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Zusammenfassung 
 
Das hepatozelluläre Karzinom (HCC) ist weltweit die fünfthäufigste Tumorerkrankung 
und die dritthäufigste durch Krebs hervorgerufene Todesursache. Mit einer jährlich 
steigenden Inzidenz und schlechter Prognose, stellt HCC ein großes 
Gesundheitsproblem dar. Diagnostische Marker zur Früherkennung des 
hepatozellulären Karzinoms werden benötigt, fehlen aber aufgrund der Komplexität 
und Heterogenität der Erkrankung. 
Das Ziel dieser Arbeit war es, die Wisp1 Expression in unterschiedlichen 
Tumorstadien zu untersuchen und die Funktionen von Wisp1 in epithelialen- und 
fibroblastischen HCC abstammenden Zelllinien zu untersuchen. 
Immunhistochemische Färbungen von HCC Patientenproben wiesen eine erhöhte 
Wisp1 Expression in ganz frühem und frühem HCC auf, wobei inflammatorische und 
steatotische Bereiche der Leber ebenfalls positiv für Wisp1 waren. In 
fortgeschrittenen HCC Stadien wurde hingegen kein Wisp1 detektiert. Diese Befunde 
wurden durch in vitro Untersuchungen ergänzt, die zeigten, dass Wisp1 von HCC 
Zellinien (FLC4, HLF) exprimiert und sekretiert wird. Eine Stimulation der epithelialen 
HCC Zelllinie (FLC4) mit humanem Wisp1 (hWisp1) führte zu einem Anstieg der 
Proliferation, während hWisp1 einen stimulierenden Effekt auf das 
Migrationsverhalten der fibroblastischen HCC Zelllinie (HLF) hatte.  
Interessanterweise wiesen beide Zelllinien eine Aktivierung von Signalwegen über 
die Phosphorylierung von Fak, Src, Akt und Erk1/2 auf. Alles, in der Entwicklung von 
HCC, wichtigen Phospokinasen.  
In der vorliegenden Arbeit wurde Wisp1 als möglicherweise geeigneter 
immunhistochemischer Marker für die Früherkennung  des HCC identifiziert. Darüber 
hinaus könnte Wisp1 auch kausal mit der Erkrankung assoziiert sein, da es die 
Proliferation und Migration von HCC Zellinien reguliert. 
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1 Introduction 
1.1 Hepatocellular carcinoma (HCC) 
Worldwide, hepatocellular carcinoma (HCC) is the fifth most commonly diagnosed 
solid cancer and the third most common cause of cancer related death with a 5-year 
survival rate of only 3−5% upon diagnosis [1]. Because of its constantly increasing 
incidence and its very poor prognosis, HCC represents a major health problem  [2]. 
So far, the underlying mechanism of HCC is poorly understood and available factors, 
which could be used as early diagnostic markers supporting therapy, are limited. 
Commonly used biomarkers are, for instance, α–fetoprotein, alkaline phosphatase, 
gamma-glutamyl transpeptidase (GGT), ferritin and hepatoma-specific gamma-
glutamyl transferase isoenzymes [3, 4]. However, none of these factors are specific 
for HCC, which is a highly complex disease and, due to its heterogeneity, its 
pathogenesis is understudied when compared to other frequent cancer diseases like 
breast or lung cancer. Different risk factors, such as hepatitis B and C infection, 
prolonged exposure to toxins, like Aflatoxin B1 intoxication, and chronic abuse of 
alcohol may account for the high variability of HCC. Hepatitis B infection and 
Aflatoxin B1 intoxication are the main risks for HCC in Africa and Asia, whereas 
hepatitis C infection and alcohol abuse account for HCC in developed countries [5]. 
Other risk factors have been proposed to play a role in HCC with a lower frequency, 
including diabetes, non-alcoholic fatty liver diseases (NAFLD) or certain metabolic 
disorders [6]. HCC can result from chronic liver inflammation on the basis of one of 
these aforementioned risk factors. Another important factor is gender, since females 
show a 3 fold lower incidence of HCC than males [7]. HCC affects all parts of the 
world with some geographical variations; the highest incidence rates can be found in 
developed countries. Likewise, the geographic distribution of risk factors varies. 
 
1.1.1 Mechanisms of hepatocellular carcinoma 
 
The development of HCC must be understood as a multistep process with an 
accumulation of genetic and epigenetic alterations in regulatory genes which 
eventually lead to uncontrolled activation of oncogenes and inactivation, or even loss, 
of tumor suppressor genes [8]. The molecular contribution of these multiple factors 
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and their interactions in the development of HCC remain elusive [9]. Finally, these 
multiple steps trigger the malignant transformation of normal hepatocytes (HCs) into 
cancer cells [9] (Fig.1-1). One of the first steps toward HCC is the development of 
hyperplastic nodules; thereby hepatocellular carcinoma is grouped into tumors which 
are poorly, moderately or well differentiated. Poorly differentiated tumors are the most 
malignant type of HCC.  At advanced-stages of disease, tumor cells may metastasize 
into other organs such as the lung [10]. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1-1 Progression of hepatocellular carcinoma. Liver damage due to different risk factors such as 
hepatitis B or C infection, cirrhosis or chronic alcohol abuse leads to hepatic necrosis followed by 
hepatocyte proliferation. Continuous regeneration in chronic liver disease is characterized by the 
formation of hyperplastic nodules which develop into dysplastic nodules and finally into hepatocellular 
carcinoma (HCC) which can be grouped into well, moderately or poorly differentiated tumors. [From 
Farazi, P.A. and R.A. DePinho, Hepatocellular carcinoma pathogenesis: from genes to environment. 
Nat Rev Cancer, 2006. 6(9): p. 674-87] 
 
Various genetic alterations of different pathways are involved in the progression of 
hepatocellular carcinoma. For example, molecular analysis of human HCC has 
shown inactivation of the tumor suppressor gene p53 and E-Cadherin, and 
deregulation of transforming growth factor beta (TGF-β) and vascular endothelial 
growth factor (VEGF) dependent signaling [6]. In addition, aberrant DNA methylation 
patterns have been reported in human HCC and telomere shortening has been 
described as a key feature of chronic hyperproliferative liver disease [6]. Several 
genomic alterations can also lead to defects in chromosome segregation, a common 
cytogenetic feature of cancer cells including HCC [6]. Alterations of the Wnt pathway 
and its components, e.g., β-catenin and glycogen synthase kinase (GSK-3β), have 
been proven to be crucial in hepatocarcinogenesis [6].  
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A common hallmark of all cancers is abnormal growth control. Since multiple 
signaling pathways and genetic alterations can result in uncontrolled growth or 
migration, it is very important to understand the complexity of HCC. More information 
on prognostic factors and molecular biomarkers associated with liver tumorigenesis 
should bring forward therapeutic approaches.  
 
 
1.1.2 Therapeutic perspectives for hepatocellular                
carcinoma and staging systems of the disease 
 
At the present time, limited therapeutic options exist and these options are applicable 
for just a select number of HCC patients [11]. Standard curative methods are surgical 
resection or liver transplantation, percutaneous or transanterial interventions, 
radiation therapy and chemotherapy [9]. However, these curative treatments are 
applicable for only 30−40 % of HCC patients [12, 13]. 
The stage of HCC at diagnosis limits treatment options and prognosis. Very early-
stage HCC has been defined as the disease in patients with well-preserved liver 
function; these patients show the best survival rate upon partial hepatectomy. Early-
stage HCC has been defined as a tumor between 3 and 5 cm; liver transplantation 
gives the best possible outcome. This situation is complicated since diagnostic 
markers for early-stages of HCC, which potentially would allow for effective 
treatment, are lacking, thus diagnosis is made at an intermediate or advanced-stage 
of the disease where no radical treatments are applicable. For intermediate or 
advanced-stage HCC, local ablative therapy is most commonly used. These patients 
have a survival time of 6 months to 2 years [14]. Promising survival benefit is shown 
with the treatment of patients with advanced HCC with the multikinase inhibitor 
sorafenib [14]. Patients with end-stage HCC do not benefit from any known treatment 
since most die of liver failure and not from tumor progression. 
In this context, different HCC staging and grading systems are available and provide 
a detailed characterization of HCC to find the suitable treatment for each subgroup of 
patients [13]. Traditionally, the Tumor-Node-Metastasis (TNM) classification system 
or the Okuda classification is used. Both systems have their limitations, as TNM 
staging does not include liver function and the Okuda system cannot distinguish 
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between early and advanced HCC stages. The Barcelona Clinic Liver cancer 
classification (BCLC) system, first presented in 1999, combines tumor status with 
liver function and general health status [15]. It has been proposed as the standard 
means to assess for prognosis of patients with hepatocellular carcinoma. 
 
 
1.1.3 Epithelial-mesenchymal transition (EMT) during          
HCC progression 
 
The process of epithelial cells converting into mesenchymal cells is named epithelial-
mesenchymal transition (EMT). EMT is a complex process by which differentiated 
epithelial cells lose their epithelial cell phenotype and obtain features of 
mesenchymal cells [16]. Epithelial cells express E-Cadherin, whereas mesenchymal 
cells do not [17]. Epithelial cells show a polygonal-shaped morphology. They form 
cell layers closely connected by adherent, gap and tight junction proteins. Under 
normal conditions, they do not leave their epithelial cell layer. Furthermore, epithelial 
cells show an apical to basolateral polarization, with the apical surface usually facing 
the lumen of a body cavity and the basolateral membrane in contact with other cells 
or ECM components. In contrast, mesenchymal cells show a spindle-shaped, 
fibroblast-like morphology. They are highly mobile, migrating as chains or single cells, 
lacking the apical to basolateral polarization of epithelial cells [16]. EMT is initiated by 
a diverse set of extracellular signals, for instance, through extracellular matrix 
components or growth factors, which further stimulate intracellular factors like 
members of the GTPase family and Src tyrosine-kinase family members. These 
signaling pathways eventually lead to the modulation of transcription, and thus, 
changes in EMT specific gene-expression. EMT plays a central role during cancer 
progression since cancer cells undergo partial or complete EMT [16]. With this 
transition, cancer cells acquire a high motility and migrative capacity, which gives 
them the possibility to break through the basement membrane, invade blood vessels 
and reach distant organs where they build up cancerous colonies (Fig.1-2).  
 
Introduction 
 
 14
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1-2 Sites of EMT in the emergence and progression of carcinoma. After tumor initiation, 
normal epithelium develops into an adenoma. Tumor promotion, including genetic and epigenetic 
changes, can further lead to the EMT process which is necessary for breaking through the basal 
membrane and subsequent intravasation and systemic spread. At secondary sites, solitary carcinoma 
cells can extravasate and either remain solitary (micrometastasis) or form a new carcinoma through a 
mesenchymal−epithelial transition (MET) [From Thiery, J.P., Epithelial-mesenchymal transitions in 
tumour progression. Nat Rev Cancer, 2002. 2(6): p. 442-54.] 
 
 
A key event during EMT is the loss of E-Cadherin, which is a main component of the 
epithelial cell phenotype, hence having direct consequences for cell shape. E-
Cadherins are transmembrane proteins which belong to the superfamily of calcium 
dependent adhesion glycoproteins. The N-terminal domain plays a fundamental role 
in the formation of epithelial tissues. The cytoplasmic domain interacts with β-catenin 
and the actin network, causing assembly and disassembly of actin cytoskeleton, 
thereby modulating the tension and strength of adhesion within a cell layer. Reduced 
expression of E-Cadherin is correlated with the disruption of cell-cell contacts and 
deregulation of adhesion further influencing proliferation and mobility [18]. Knock-out 
experiments revealed functions of this gene in migration and tumor progression, as 
well as invasion and metastasis [19]. 
HCC metastasis is most frequently detected in the lung, followed by regional lymph 
nodes, kidneys, bone marrow and adrenal glands. Metastasis is a process that 
depends on many factors including chemokine gradients, detachment of cell-cell 
contact between neighboring cells and changes in cell-matrix contacts. Thus, cell 
adhesion, migration and proteolysis of extracellular matrix proteins are important 
features in the process of metastasis [20, 21]. This is especially of importance in the 
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liver, where hepatocytes grow in trabecular structures surrounded by a high number 
of ECM proteins like collagen, lamin and fibronectin. Interactions between HCC cells 
and ECM proteins are suggested to be essential for tumor metastasis. Interactions 
between the HCC cells and the ECM components are mediated through integrins, a 
class of transmembrane receptors [22]. 
 
1.1.4 The role of integrin molecules as signal 
transducing adhesion factors in hepatocellular carcinoma 
cells 
Intergrins are heteromeric transmemebrane receptors. They regulate cell functions in 
each kind of cell. At least 14 distinct alpha chains and 9 beta subunits are known that 
can pair up to form more than 20 different receptors [22]. Each subunit has an 
extracellular and a cytoplasmic domain. While the extracellular domain binds to 
extracellular-matrix (ECM) proteins, the intracellular domain interacts with signaling 
molecules and actin binding proteins linking integrins to the components of the 
cytoskeleton. Integrins have been shown to be important signal transducers; they 
modulate cell-cell contacts and they participate in cell migration, growth and 
inflammation. During carcinogenesis, integrins were described to influence tumor 
growth, differentiation, survival and apoptosis during the metastasis of cancer cells 
[23, 24]. Integrins mediate signals from the surroundings to the inside (“outside-in”) of 
the cell. On the other hand, “inside-out” signaling pathways involving factors that bind 
directly to the cytoplasmic tails and phosphorylation events can also modulate 
integrin function [25]. Many cancer cells interact with cell and matrix components 
through integrins [22]. Integrin function can be altered by ligands present in, and 
produced by, HCC [26]. Furthermore, integrin signaling was linked to both cancer 
suppression and progression [27].  
 
1.2 The CCN family of proteins 
 
The CCN family of proteins was originally discovered in the 1990s. However, they 
remained mostly understudied in the field of cell and cancer biology until only 
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recently. It has become clear that the CCN proteins are multifunctional factors which 
are involved in many important processes including differentiation, tumorigenesis, 
wound healing, cell proliferation, migration, adhesion and survival [28].  
The abbreviation CCN stands for Cyr61 (cysteine-rich 61), CTGF (connective tissue 
growth factor) and Nov (nephroblastoma overexpressed), which are the first three 
discovered and best investigated proteins of this family. Currently, the family 
comprises six family members including Wisp1, Wisp2 and Wisp3 (WNT1-inducible-
signaling pathway proteins). As they were discovered simultaneously by different 
laboratories, individual proteins often carry different names in literature [29]. To avoid 
confusion resulting from this nomenclature, they were recently named after the 
founding proteins (CCN) and numbered 1-6 (Tab.1-1).  
 
Tab. 1-1 Conventional and alternative nomenclature of the CCN protein family. 
 
 
Importantly, CCN proteins are so called “matricellular proteins”, which do not directly 
play a structural role in the matrix, but serve to modulate cell matrix interactions and 
cell function [30]. The functions of this group of proteins are achieved by binding to 
matrix proteins, cell surface receptors or other molecules, such as cytokines or 
proteases which interact with the cell surface [30]. In general, one of the key features 
of matricellular proteins, and of CCN proteins in particular, is their enormous range of 
functions resulting from a multi-modular structure [31]. The typical CCN protein is 
composed of four potentially functional modules [32]: The N-terminal signal sequence 
for secretion is followed by four modules including an IGFBP domain, a von 
Willebrand factor type C (VWC) oligomerization domain, a thrombospondin type 1 
repeat (TSP-1) and a carboxyl terminal end (CT) (Fig.1-3). The second remarkable 
feature of the CCN family is their high cysteine content (about 10% by mass). Despite 
CCN nomenclatur Alternative nomenclature 
CCN1 
CCN2 
 
CCN3 
CCN4 
CCN5 
CCN6 
Cyr61, CEF10, IGFBP-rP4m, βIG-M1, CTGF-2, IGFBP10 
CTGF, βIG-M2, FISp12, IGFBP-rp2, IGFBP8, HCs24, HBGF- 
0.8  
Nov, IGFBP-rP3, IGFBP9 
Wisp1, Elm1 
Wisp2, CTGF-L, CTGF-3, HICP, rCOP-1 
Wisp3 
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the fact that they share a high similarity in structural components, closely related 
CCN proteins may show both, similar or even opposite effects on, e.g., cell 
proliferation, migration or survival. Furthermore, it is important to note that the 
function of CCNs is also dependent on the cellular context and the 
patho/physiological condition [33]. 
 
 
Fig.1-3 Representative structure of CCN proteins. VWC: von Willebrand factor type C, TSP-1:  
thrombospondin type 1 repeat, CT: carboxyl terminal end, SP: signal peptide, BMP: bone 
morphogenetic protein, LRP: low density lipoprotein receptor-related protein, VEGF: vascular 
endothelial cell growth factor, HSPG: heparan sulfate proteoglycans. 
 
The multi-modular structure is the basis for a diverse set of putative CCN interactions 
and results in multiple CCN functions. Each module has its own biological role and 
can either act independently or in a cooperative manner with the other modules 
present in the same CCN protein. Of high interest is that CCN proteins are present in 
the extracellular milieu as they are secreted proteins. Using specialized transport 
vesicles, they are transferred to the membrane of the cell surface where they are 
released. On the other hand, CCN proteins can be internalize in an endocytotic way 
[34]. Modulation of the IGFBP domain for instance directly affects cell cycle 
progression or cell death [35]. The most common functions of the von Willebrand 
factor type C is the regulation of bone morphogenic proteins (BMPs) and 
transforming growth factor beta (TGF-β), thereby affecting cell adhesion or tissue 
remodeling [36]. The TSP-1 domain has a huge number of interaction partners such 
as collagen [37], fibronectin [38], and VEGF [39], affecting cell adhesion or 
modulating angiogenesis. Additionally, the TSP-1 domain binds to integrins [40] and 
this integrin binding has been thought to be important for CCN functions [41]. 
Furthermore, the CT domain of CCN proteins for instance regulates cell 
Module 1 Module 3Module 2
IGFBP domain VWC domain TSP-1 domain CT domain
TGF-β, BMP4,
integrins
integrins, 
LRP-1, VEGF
heparin, LRP-6,
notch, fubulin 1,
VEGF,
SP
IGFinteraction partners
modular structure
domains
Module 4
domain function Golgi- IGF-binding oligomerization cell-attachment dimerization
targeting
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differentiation through Notch1 [42] or binds to heparan sulfate proteoglycans 
(HSPGs) [43, 44] which are considered to act as a co-receptor for integrins. This 
complex forms the putative receptor for CCN proteins and mediates some of their 
functions. Upon binding of CCN ligands and activation of cell surface receptors, 
integrin−HSPG complexes induce further downstream events in the cytoplasm 
including activation of different kinases (e.g., MAP-kinases) and gene transcription 
[33, 41, 42, 44-47] (Fig.1-4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1-4 Scheme of CCN protein regulation and function. HSPG: heparan sulfate proteoglycans, 
MAPK: mitogen-activated protein kinase, FAK: focal adhesion kinase; PI3K: phosphatidylinositol 3-
kinase.  
 
Thereby, one of the first functions awarded to CCN members was the deregulation of 
cell proliferation. Due to their multifunctional properties and expression in different 
types of cells and tissues, CCN proteins might be important molecules for the 
prognosis and diagnosis of HCC and may represent promising targets for therapy 
[29, 41, 48].  
extracellular
intracellular
CCN functions
MAPK
FAK RhoA
PI3K
Rho 
GTPases
cytokines
infection stressCCN regulation
CCN
tumor growth
differentiation
wound healing
inflammation
fibrosis
cell cycle
control
adhesion
migration
extracellular
matrix
production
biological processes           cellular functions
integrins
HSPG
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1.3 The Wnt-inducible signaling protein 1 (Wisp1/CCN4) 
 
Wnt-inducible signaling protein 1 (Wisp1/CCN4) is a secreted, matricellular, cysteine-
rich protein of the CCN family of proteins. It was first described in low metastas type 
melanoma in the mouse and called Elm1 (expressed in low-metastatic type 1 cells) 
[49]. Human Wisp1 was later discovered as a Wnt-induced downstream target in the 
mammary epithelial cell line C57MG [50]. Wisp1 is poorly investigated; very few 
studies exist which report the analysis of Wisp1 expression and function [51, 52] and 
those that do exist report on several organs, such as the heart, kidney, breast and 
lung [53-55]. In general, Wisp1 was found to be expressed during organ 
development, in diseases linked to fibrotic changes of tissues or organs and in 
cancer. Wisp1 expression was mainly linked to cell differentiation, proliferation, 
adhesion, migration and extracellular matrix production. However, the molecular 
mechanism of Wisp1 function is unclear. Until now, most reports describe PI3K/Akt 
dependent signaling as an intracellular effector of Wisp1 [53, 54], partially explaining 
the effect of Wisp1 on cell proliferation and survival. A signaling pathway whereby 
Wisp1 affects cancer development and metastasis formation has not been reported 
thus far. In contrast to other members of the CCN family, binding of Wisp1 to 
integrins has not been shown, however, binding to the soluble and matrix-associated 
dermatan sulfate proteoglycans, decorin and biglycan, has been described 
recently [56]. 
Since Wisp1 was first described as a downstream target of the Wnt signaling 
pathway [57], an important pathway frequently altered in human hepatocellular 
carcinoma [58], it is of particular interest to study its expression and function in 
normal, injured and diseased liver. Subsequently, Wisp1 is suggested to interact with 
cell-surface receptors, such as integrins [44] , Notch [50] and connexins [59, 60], 
comprising signaling pathways that play an important role in normal and injured liver 
[61, 62]. Wisp1 was described as a suppressor of metastasis [49]. Recently, Wisp1 
has been found to be overexpressed in cholangiocarcinoma [63]. Using 
immunohistochemistry, expression of Wisp1 was not detected in normal liver but was 
detected in about 50% of cholangiocarcinoma tissues. In addition, Wisp1 expression 
was reported to be significantly associated with lymphatic and perineural invasion of 
tumor cells [63], an oncosuppressor gene in colorectal cancer [64] and 
overexpressed in scirrhous gastric carcinoma [59]. Thus, Wisp1 is described to have 
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either pro- or anti-cancerogenic effects. Recently, Wisp1 was observed to mediate 
cell signaling not only in an autocrine loop (overexpression resulted in morpholocial 
alterations of normal fibroblasts) [58], but also in a paracrine loop supporting 
tumorigenesis [58, 64]. Moreover, expression of Wisp1 and its alternative splice 
variants was described in different HCC cell lines [60] and in vivo in HCC [61]. A 
comprehensive approach toward the expression and function of Wisp1 in HCC is 
missing until now, but could provide helpful insights into one of the most malignant 
tumor types worldwide. 
 
1.4 Aims of this study 
Hepatocellular carcinoma is a malignant liver tumor with the ability to rapidly 
progress. Since therapeutic regimes for its treatment are limited, diagnosis and 
intervention at an early-stage is mandatory to improve prognosis.  
The aim of the present study was to investigate whether the expression of Wisp1 is 
associated with different stages of HCC. To elucidate the underlying mechanisms, 
Wisp1 signaling was studied in human epithelial- and fibroblastoid-type HCC-derived 
cell lines. In vivo, I sought to determine characteristic features of Wisp1 expression 
during HCC progression which might help to identify early morphological and 
phenotype specific alterations of hepatocytes at early stages of HCC. In vitro, I 
investigated Wisp1 expression and secretion in HCC derived cell lines of different 
phenotypes to elucidate further the Wisp1 mechanism of signal transduction and its 
impact on proliferation and migration. 
This study therefore aims to analyze Wisp1 to identify a new marker for early stages 
of HCC, allowing interventions at an early time point, and should provide evidence 
that Wisp1 drives cancer specific proliferation and migration. 
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2 Materials and methods 
2.1 Equipment 
Agarose chamber    PeqLab, Germany 
Analytical balance BL310  Sartorius, Germany 
Autoclave    NTAS, Germany 
Blotting chamber   PeqLab, Germany  
Electrophoresis chamber  Bio-Rad, USA 
Cell Incubator, Hera cell  Kendro Laboratory Products, Germany 
Centrifuge, Biofuge primo R Heraeus, Germany 
Confocal microscope  Leica, Germany 
DMIRE2 confocal microscope Leica, Germany 
DC500 phase contrast/ 
ELISA, Infinite Reader M200 Tecan, Germany 
Flow cytometer, FACSCalibur      PeqLab, Germany 
Fluorescent microscope  Leica, Germany 
Hemocytometer   Hecht, Germany 
Leica RM 2165 microtome  Leica, Germany 
Laminar flow HA2472GS  Heraeus, Germany 
Luminescent image analyser PeqLab, Germany 
Magnetic stirrer MR 3001K Heraeus, Germany 
Microwave    Sharp, Germany 
MOS52 microscope  Leica, Germany 
PCR-thermocycler   Bio-Rad, USA 
Spectrometer, Gene Quant Pro Amersham Bioscience, USA 
Thermomixer compact  Eppendorf, Germany 
UV transilluminator   NTAS, Germany 
Vortexter Heidolph REAX top Buddeberg, Germany  
Water bath    VWR, Germany 
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2.2 Patients and tissue samples 
HCC tissues and corresponding non-cancerous hepatic tissues were obtained with 
consent from 54 patients who had undergone curative hepatectomy for primary HCC 
in the Eastern Hepatobiliary Hospital of Second Military Medical University, Shanghai, 
China. All patients are exclusively Han Chinese. The study protocol was approved by 
the Ethical Committee of Eastern Hepatobiliary Hospital of Second Military Medical 
University and conducted in accordance with the official recommendations of the 
Chinese Community Guidelines. Complete clinical data were available in all cases. 
The diagnosis was determined according to the UICC TNM classification of primary 
liver cancer, 6th edition [65]. Immediately after hepatectomy, fresh tumors and non-
cancerous hepatic tissues were partly snap-frozen in liquid nitrogen and stored at 
−80°C. They were partly embedded in freshly molten paraffin in an embedding box 
and poured paraffin blocks were stored at RT until further histological analysis (see 
2.3/2.4).  
 
2.3 Paraffin sectioning of human HCC tissue samples 
Tissue of the paraffin blocks (see 2.2) was cut into serial sections of 4 µm thickness. 
Cuts were transferred to a water bath filled with 37°C dH 2O and fixed on poly-L-lysine 
coated slides. Slides were incubated for 1h at 60°C  in an upright position to dry 
sections and ensure fixation. For further histological applications slides were stored 
at 4°C (see 2.4).  
 
 
2.4 Immunohistochemistry 
  
Buffers 
 
Tab. 2-1 Composition of 1x PBS buffer. 
 
 
 
 
 
 
 
 
 1 l 
instamed PBS 
ddH2O,  add to 1 l 
9.55 g 
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Tab. 2-2 Composition of Tris(hydroxymethyl)aminomethane (Tris), pH 7.6. 
 
 
Tab. 2-3 Antigen-retrieval solution, Ethylenediaminetetraacetic acid (EDTA), pH 8.4. 
 
 
Tab. 2-4 Composition of 3,3’-diaminobenzidine tatrahydrochloride (DAB) stock solution. 
 
 
 
 
 
 
 
 
 
 
Tab. 2-5 Composition of DAB staining solution. 
 
Reagents 
Dual Enzyme Block   Dako, Germany 
Xylene    Merck, Germany 
Ethanol    Merck, Germany 
Hematoxylin solution  Merck, Germany 
Malinol    Waldeck GmbH, Germany 
PBS     Biochrom, Germany 
DAB     Sigma-Aldrich, Germany 
Tris     Sigma-Aldrich, Germany 
EDTA     Calbiochem, Germany
 MW [g/mol] 1 l [c] 
Tris  
ddH2O, add to 1l, adjust 
pH with 1M HCl 
121.14 
 
 
6.057 g 50mM 
 stock 15 ml [c] 
DAB 
H2O2 
0.07% 
30% 
15 ml 
12 µl 
0.07% 
0.024% 
 MW [g/mol] 1 l [c] 
EDTA 
ddH20, add to 1l, adjust  
pH with 1M HCl 
372.2         0.3722 g 1 mM 
 15 ml [c] 
DAB 
Tris(hydroxymethyl)aminomethane 
pH 7.6, add to 15ml 
10 mg 0.07%  
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Background 
Immunohistochemistry (IHC) is a method to localize antigens or proteins in tissue 
sections. Labelled antibody-antigen complexes are visualized by enzymes, 
fluorescent dyes or colloidal gold. In this study, IHC was used to understand the 
distribution and localization of Wisp1 in human hepatocellular carcinoma tissues. 
 
Protocol 
During the whole procedure, the human HCC tissue slides (see 2.3) were not allowed 
to dry at any time. Tissue slides were first deparaffinized in three washes of xylene 
for 5 min each. Rehydration was carried out with two washes of 100% EtOH for 5 min 
each, followed by one wash of 98% EtOH for 5 min. Afterwards tissue sections were 
washed 5 min in ddH2O and in PBS. Antigen retrieval was performed by boiling 
tissue slides for 4 min in EDTA buffer (1 mM ) followed by sub-boiling for 10 min 
(microwave setting 3). Slides were cooled for 30 min at room temperature (RT) and 
then incubated with dual Enzyme Block solution for 30 min at RT to minimize 
unspecific binding of the antibodies. After 30 min the blocking solution was removed 
and replaced by primary antibody solution (see Tab.8-2). The sections were 
incubated overnight at 4°C in the primary antibodie s solution using a humidified box. 
Following overnight incubation, this step was prolonged for one additional hour at RT. 
Then, the primary antibody solutions were discarded and replaced by secondary 
antibody solutions (see 7.3.2) for 35 min at RT. Not or unspecifically bound 
secondary antibodies were removed by three consecutive washing steps in PBS for 5 
min each. To visualize the antigen-antibody complexes, tissue slides were incubated 
for a maximum of 10 min with DAB staining solution. DAB is a substrate for the 
peroxidase linked secondary antibody used as a chromogen for the 
immunoperoxidase based staining. Finally, the reaction was stopped by washing the 
slides with PBS 2 times. Counterstaining of the nuclei with hematoxylin was done by 
incubating the DAB stained sections for 10 s in Hematoxylin solution, followed by 
washing with tap water for 5 min. Tissue sections were dehydrated by two washes of 
100% EtOH for 15 s each and then cleared by incubation with three washes in 
xylene. Malinol, a nonaqueous mountant was used to embed the sections using 
glass-coverslips. The intensity of positive staining was graded from 0 to 3 (0, 
negative; 1, weak brown staining; 2, moderate brown staining; 3, very strong brown 
staining). 
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2.5 Cell culture 
2.5.1 HCC cell line culture 
 
Reagents 
Cell culture reagents 
DMEM medium     Biozol, Germany 
Cell culture additives 
Fetal bovine serum     Sigma-Aldrich, Germany 
L-Glutamin (L-Glu), 200 mM   Cambrex , Belgium 
Penicillin-Streptomycin (P/S), 100x  Cambrex , Belgium 
Trypsin      PAA Laboratories, Austria 
HBSS       PAA Laboratories, Austria 
 
 
Tab. 2-6 Composition of DMEM complete medium for HCC cell lines. 
 
 
 
 
 
 
 
 
Tab. 2-7 Composition of DMEM serum-free medium for HCC cell lines. 
 
 
 
 
 
 
 
Background 
Human HCC cell lines, FLC4, HLF, Heb3B and HCC-T have been described 
previously [66-69]. All HCC cell lines were a kind gift from Michael Kern (Institute of 
Pathology, Heidelberg, Germany). FLC4 cells were established from the human 
hepatocellular carcinoma cell line JHH-4. The JHH-4 cells were originally resected 
from a liver tumor (1988). FLC4 cells represent cells of epithelial- phenotype. FLC4 
cells are known to have preserved liver functions, such as albumin synthesis, 
including hepatic enzyme activity that contributes to drug metabolism. In addition, 
they are well differentiated cells and express E-Cadherin. HLF cells were established 
DMEM 
FCS 
L-Glu 
P/S 
500 ml 
50 ml 
5 ml 
5 ml 
DMEM 
L-Glu 
500 ml 
5 ml 
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in vitro from the hepatocellular carcinoma of a 68 year old patient (1975). In contrast 
to FLC4 cells, HLF represents cells of fibroblastoid-phenotype, they are also poorly 
differentiated cells which show spindle shaped morphology and do not express 
albumin or E-Cadherin.  
 
Protocol  
HCC cells used in this study were cultured up to passage 10 in DMEM complete 
medium at 37°C in a humidified incubator (5% CO 2, 95% air). For experiments, cells 
were serum starved overnight. All stimulations were performed in DMEM serum free 
medium at a cell density of 60-80%.  
 
 
2.5.2  Hek293T/17 cell culture 
 
Reagents 
Cell culture reagents 
DMEM medium     Biozol, Germany 
Cell culture additives 
Fetal bovine serum     Sigma-Aldrich, Germany 
L-Glutamin (L-Glu), 200 mM   Cambrex, Belgium 
Penicillin-Streptomycin (P/S), 100x  Cambrex, Belgium 
Trypsin      PAA Laboratories, Austria 
HBSS       PAA Laboratories, Austria 
 
 
Tab. 2-8 Composition of DMEM complete medium for Hek293T/17 cells. 
 
 
 
 
 
 
 
 
Tab. 2-9 Composition of DMEM serum-free medium for Hek293T/17 cells. 
 
 
 
 
 
DMEM 
FCS 
L-Glu 
P/S 
500 ml 
50 ml 
5 ml 
5 ml 
DMEM 
L-Glu 
500 ml 
5 ml 
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Background 
Hek293T/17 are a human embryonic kidney cell line with epithelial morphology, 
which was immortalized using adenoviral DNA. These cells contain the SV-40 large 
T-antigen for an efficient replication of plasmids useful for many transfection 
experiments [70].  
 
Protocol 
In this work Hek293T/17 were used for lentiviral production. They were cultured in 
complete DMEM medium and, split two times a week at a ratio of 1:4 using trypsin. 
Frequent passages kept the Hek293T/17 as individual cells to ensure high 
transfection efficiencies (see 2.22). 
 
 
2.5.3 HT1080 cell culture 
 
 
Reagents 
Cell culture reagents 
RPMI medium     Biozol, Germany 
Cell culture additives 
Fetal bovine serum     Sigma-Aldrich, Germany 
L-Glutamin (L-Glu), 200 mM   Cambrex, Belgium 
Penicillin-Streptomycin (P/S), 100x  Cambrex, Belgium 
Trypsin      PAA Laboratories, Austria 
HBSS       PAA Laboratories, Austria 
 
 
Tab. 2-10 Composition of RPMI complete medium for HT1080 cell line. 
 
 
 
 
 
 
 
 
 
 
RPMI 
FCS 
L-Glu 
P/S 
500 ml 
50 ml 
5 ml 
5 ml 
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Background 
The human fibrosarcoma cell line HT1080 (American Type Culture Collection, 
Rockville, MD) was established from a 35 year old patient. Cells were used in this 
study as transducer cells to determine lentiviral titers (see 2.22). 
 
Protocol 
HT1080 were cultured in RPMI complete medium. They were split one time per week 
at a ratio of 1:10 using trypsin. Lentiviral transfection was carried out in complete 
RPMI medium (see 2.22). 
 
2.6 Protein isolation of cultured cells 
Buffers 
 
Tab. 2-11 Composition of 1x Ripa Protein Lysate buffer, stock solution. 
 
 
Tab. 2-12 Composition of 1x Ripa Protein Lysate buffer, pre-working solution 
 
 
 
 
 
 
 
 
 
Reagents 
HBSS       PAA, Germany 
 MW [g/mol] 300 ml [c] 
Tris 
NaCl 
Nonident P40 
EDTA  
sodium dodecyl sulfate (SDS) 
DOC( Deoxycholic acid Na-salt) 
ddH2O, add to 300 ml, adjust pH  
7.2 with 1 M HCl 
121.14 
58.44 
100% 
372.2 
288.38 
392.57 
1.815 g 
4.383 g 
6 ml 
0.279 g 
0.3 g 
1.6 g 
50 mM 
250 mM 
2% 
2.5 ml 
0.1% 
0.5% 
1x Ripa Protein Lysate buffer 
Complete protease inhibitor  
cocktail tablets 
50 ml 
1 x 
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Complete protease inhibitor cocktail tablets Roche, Germany 
Phosphatase inhibitor cocktail 2   Sigma Aldrich, Germany 
 
Protocol 
Medium of cultured cells was aspirated and cells were washed twice with HBSS. 
Cells were lysed with ice-cold Ripa buffer (Tab.2-12) supplemented with phosphatase 
inhibitor cocktail 2 (1:100). For 6 well plates, 120 µl Ripa was used and, for 12 well 
plates 60 µl of Ripa buffer. Cells were further shaken for 20 min on ice. The cell 
lysate was disrupted by force using a cell scratcher. Cell lysates were collected in 1.5 
ml tubes and centrifuged for 20 min at 13.000 rpm. The supernatant was collected 
and protein concentration was determined (see 2.7) 
 
2.7 Protein quantification  
 
Kits 
Biorad protein assay kit (500-0113, 500-0114, 500-0115)  Biorad, Germany 
Dc Assay reagent A, alkaline copper tartrate 
Dc Assay reagent B, folin reagent 
Dc Assay reagent S, surfactant solution for colorimetric assays 
 
Reagents 
Bovine serum albumin (BSA) standard solutions (in PBS): 1 µg/ml, 2 µg/ml, 4 µg/ml, 
6 µg/ml, 8 µg/ml, 10 µg/ml 
 
Background 
Protein quantification according to the Lowry method is a colorimetric assay to 
determine the total amount of protein in a solution. The Lowry assay is based on 
reduced copper ions in alkaline solution, which reduce the folin-ciocalteau-reagent by 
the oxidation of peptide bonds. The reduced folin reagent can be measured by 
spectrophotometry.  
In this study, a modified Lowry assay was used to determine the amount of isolated 
proteins from HCC cell lines (see 2.5.1) for subsequent Western blot analysis (see 
2.8).  
Materials and methods 
 
 30
Protocol 
2 µl of protein lysate, BSA standards and blank value ddH2O were mixed with 20 µl of 
Assay reagent A and S (10:1) and immediately incubated with 200 µl of Assay 
reagent B. Reaction mixtures turned slightly blue within 15 min incubation at RT. 
Absorbance was measured at a wavelength of 690 nm. Total protein concentration 
was calculated by a BSA standard curve (BSA concentration against absorbance 
values). 
 
2.8 Western blot analysis 
 
Buffers 
 
Tab. 2-13 Composition of 1M Tris-HCl, pH 8.8/ 6.8. 
 
Tab. 2-14 Composition of 10% Sodium dodecyl sulfate solution. 
 
 
 
 
 
 
 
Tab. 2-15 Composition of separating gels for Western blot. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  MW [g/mol] 1 l [c] 
Tris 
ddH2O, adjust to 1 l,  
adjust pH with 1 M HCl 
121.14 121.14 g 1 M 
Sodium dodecyl sulfate 
ddH2O, adjust to 100 ml 
10 g 
 10% 12% 
Acrylamide/bisacrylamide solution  5:1 
1 M Tris-HCl, pH 8.8 
ddH2O 
10% sodium dodecyl sulfate solution (SDS) 
N,N,N’,N’-tetramethylethylenediamine (TEMED) 
10x ammonium persulfate (APS) 
2.5 ml 
1.6 ml 
2.2 ml 
66.7 µl 
3.2 µl 
32.5 µl 
1.8 ml 
1.4 ml 
2.3 ml 
56 µl 
2.8 µl 
28 µl 
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Tab. 2-16. Composition of stacking gel for Western blot. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tab. 2-17 Composition of 10x Lämmli electrophoresis buffer. 
 
 MW [g/mol] 1 l [c] 
Tris 
Glycine 
10% sodium dodecyl sulfate solution (SDS) 
ddH2O, add to 1 l 
121.14 
75.07 
30,34 g 
144 g 
100 ml 
250 mM 
1,92 M 
1% 
 
Tab. 2-18 Composition of Transfer buffer. 
 
Tab. 2-19. Composition of 10x TBS. 
 
 
 4% 
Acrylamide/bisacrylamide solution  5:1 
1 M Tris-HCl, pH 6.8 
ddH2O 
10% sodium dodecyl sulfate solution (SDS) 
N,N,N’,N’-tetramethylethylenediamine (TEMED) 
10% ammonium persulfate (APS) 
0.3 ml 
0.5 ml 
1.1 ml 
19.1 µl 
1.9 µl 
9.4 µl 
 MW [g/mol] 1 l [c] 
Methanol 
Nupage® Transfer Buffer 
ddH2O, add to 1 l 
100% 
20x 
200 ml 
50 ml 
20% 
1x 
 MW [g/mol] 1 l [c] 
Tris 
NaCl 
ddH2O, add to 1 l, adjust pH 7.8 with 1 M 
HCl 
121.14  
58.44  
12.1 g 
87,66 g 
100 mM 
1.5 M 
Materials and methods 
 
 32
Tab. 2-20 Composition of 1x TBST (0.1% Tween). 
 
 
 
 
 
 
 
 
Tab. 2-21 Composition of 0.1 M Tris, pH 8.5. 
 
Tab. 2-22 Composition of 1x TBST blocking solution (5% milk powder). 
 
 
 
 
 
 
Tab. 2-23 Composition of ECL Western blotting detection reagent A. 
 
 
 
 
 
Tab. 2-24 Composition of ECL Western blotting detection reagent B. 
 
 
 
 
 
 
 
 
 
Reagents 
Molecular weight standard: 
Prestained Protein Ladder  Fermentas, Germany 
Loading Buffer   Invitrogen, Germany 
p-Coumaric acid   Sigma-Aldrich, Germany 
Luminol (3-aminophtolhydrazide) Sigma-Aldrich, Germany  
Hydrogen peroxide   Sigma-Aldrich, Germany 
Nitrocellulose membrane  Whatman, Germany 
Ponceau S solution   Sigma-Aldrich, Germany 
Nupage®Transfer Buffer              Invitrogen, Germany 
10x TBS  
Tween®20 
ddH2O, add to 1 l 
100 ml 
10 ml 
 MW [g/mol] 1 l [c] 
Tris 
ddH2O, add to 1 l, adjust pH with 1 M HCl 
121.14 12.1 g 100 mM 
 
1x TBST  
Milk powder 
50 ml 
2.5 g 
0.1 M Tris, pH 8.5 
Hydrogen peroxide solution, 30% 
5 ml 
3 µl 
0.1M Tris, pH 8.5 
p-Coumaric acid 
Luminol (3 -aminophtolhydrazide) 
5 ml 
22 µl 
50 µl 
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Filter paper    Whatman, Germany 
 
Background 
Western blot analysis is a method to detect specific proteins in a complex protein 
mixture. The proteins are separated dependent on their size by gel electrophoresis 
and then transferred to a nitrocellulose membrane where they can be visualized by 
specific antibody-antigen reactions. 
In this study, Western blot was performed to detect Wisp1 expression, secretion and 
putative components involved in its cellular signaling pathways (see 3.3/3.5/3.6). 
 
Protocol 
A protein amount of 20-35 µg was diluted in 4 x Loading Buffer (LB) to a final 
concentration of 1 x LB in 50 mM DTT. Samples were adjusted with ddH2O to a final 
volume of 40 µl. Samples were vortexted for a few seconds and incubated for 10 min 
at 99°C. Next, the samples are spun down by centrif ugation at 10.000 rpm for 5 min. 
The protein samples were loaded together with 2 µl Prestained Protein Ladder into 
the gel pockets of a self-poured SDS gel. Proteins were separated by electrophoresis 
at 60 V for 5 h using 1x Lämmli as running buffer. Then, the proteins were transferred 
from the gel to a nitrocellulose membrane in ice cold Transfer Buffer. Therefore, wet 
transfer chambers were filled with wet filter paper, sponges, gel and the membrane 
and fixed between the electrodes. From anode to cathode the setup of the blotting 
sandwich was as follows: 2 sponges, 3 sheets of filter paper, gel, nitrocellulose 
membrane, 3 sheets of filter paper, and 2 sponges. Importantly, attention was given 
to air bubbles, which were not allowed to be inside the blotting sandwich. The 
transfer of the proteins was performed at 40 mA per gel for 16 h. After blotting, 
unspecific binding of antibody was prevented by blocking the membrane in blocking 
solution for 3 washes of 10 min each. The membrane was then incubated in primary 
antibody dilutions (see Tab.8-2) overnight at 4°C o n an overhead shaker. The next 
day, the membrane was washed 3 times in TBST blocking solution for 10 min each 
and, then incubated in secondary antibody-HRP dilutions (see Tab.8-3) in TBST for 2 
h at RT. The antigen/antibody complex was visualized using enhanced 
chemiluminescent (ECL) reaction of Luminol and p-coumaric acid, catalysed by 
peroxide. The antigen chemiluminescence emission of light was scanned on a CCD 
camera.  
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2.9 Assessment of Wisp1 concentration by calibration 
To determine the concentration of Wisp1 necessary to treat HCC cells in cell culture, 
we needed to identify the level of Wisp1 which is expressed in these HCC cell lines 
(see 2.5.1) naturally during the time of culture. These cell lines were cultured for a 
day (when low Wisp1 expression was detected) up to 3 days (when both cell lines, 
FLC4 and HLF, express higher levels of Wisp1). Cell lysates were harvested (see. 
2.6) and the concentration of Wisp1 was estimated using an exact amount of 
recombinant Wisp1 protein as calibrator. In detail, HCC cell lines were seeded in 6 
well plates (350.000 cells/well) and harvested at day 1, 2 and 3. 1/20 of total 
harvested protein lysate and calibrator (25 and 100 ng/ml recombinant Wisp1 protein) 
were resolved with SDS PAGE and immunobloted. Immunoblots were quantified with 
the AIDA Image Analyzer 2.11 software and related to total number of seeded cells. 
We estimated that FLC4 cells expressed at day 3 85.4 ng of Wisp1 and HLF cells 
expressed 73.2 ng. Therefore, for this study, a concentration of 100 ng/ml Wisp1 was 
chosen to treat respective amount of cells at day 1 to simulate natural concentration 
of Wisp1 which might be found in HCC. 
 
 
2.10 Quantitative recovery of proteins from diluted 
solutions using acetone 
 
Reagents 
Acetone Merck, Germany 
 
 
Protocol 
Protein precipitation is a technique to concentrate proteins from a diluted protein 
mixture or solutions. 
In this study, precipitations were performed to detect secreted Wisp1 in conditioned 
media of HCC cells (see 3.3). 
HCC cell lines were grown in 6-well plates in 2 ml of serum free medium. After 1, 2 
and 3 days conditioned medium was harvested and mixed with ice cold acetone 
(1:4). Precipitation was performed overnight at -20°C. Precipitate was spun down for 
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20 min at 13.000 rpm (Technical Resource, Pierce Biotechnology, Acetone 
Precipitation of Proteins). The precipitated pellet was dried at RT for 4 h and further 
resolved on SDS PAGE, transferred to a nitrocellulose membrane and 
immunoblotted for detection of Wisp1 as described (see 2.8). 
 
 
2.11 mRNA Isolation, RNA electrophoresis and reverse          
transcription 
 
Kit 
RNeasy QuantiTect Reverse Transcription kit  Qiagen,Germany 
(Cat.No. 205314)       
 
Tab. 2-25 RNeasy QuantiTect Reverse Transcription kit. 
 
 
 
 
 
  
 
 
 
Buffers 
 
Tab. 2-26 Composition of DEPC water.  
 
 
 
 
 
 
 
 
 
 stock 20 µl 
Reverse transcriptase  
Primer Mix 
RT buffer 
gDNA wipeout buffer 7x 
RNA 
ddH2O 
10 
10 
5x 
10 mM 
 
1 µl 
1 µl 
4 µl 
2 µl 
1 µg 
add to 20 µl  
 stock 1 l [c] 
DEPC 
ddH2O, add to 1 l, incubate 12 h 
at 37°C, autoclave 
100% 1 ml 1% 
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Tab. 2-27 Composition of 20x MOPS running buffer. 
 
Tab. 2-28 Composition of RNA Loading buffer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reagents 
EtOH     Merck, Germany 
β-mercapthoethanol  AppliChem, Germany 
Agarose    Serva, Germany 
Formaldehyde   Merck, Germany 
Ethidium bromide solution  
(10 mg/ml)    AppliChem, Germany 
DNA Ladder (100 bp, 1kb)  AppliChem, Germany 
 
Background 
RNA isolation is a technique to purify RNA from biological samples. The quantity and 
integrity of the purified RNA can be determined by gel electrophoresis. For the 
 MW [g/mol] 1 l [c] 
Sodium acetate (NAOAc) 
EDTA 
MOPS 
DEPC water, add to 1 l,  
incubate 12 h at 37°C, autoclave 
82.03 
372.2 
209.26 
8.20g 
7.45g 
83.72 g 
0.1 M 
20 mM 
0.4 M 
 stock 12 ml [c] 
MOPS 
Formamide 
Formaldehyde 
Ficol solution 
Bromphenol blue 
DEPC water, add  
to 12 ml 
20x 
100% 
209.26 
100% 
669.96 g/mol 
8.20g 
6 ml 
2.14 ml 
1,2 ml 
1.2 mg 
1x 
50% 
2.2 mM 
10% 
0.15 mM 
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reverse transcription of single-stranded mRNA into complimentary DNA (cDNA) the 
enzyme reverse transcriptase from Qiagen was used. 
In this work, total RNA was extracted from cells using the RNeasy kit according to the 
manufacture’s instructions.  
 
Protocol  
RNA was isolated from cells grown in 6-well plates. Lysates were obtained by adding 
300 µl RLT buffer containing β-mercapthoethanol (100:1). Homogenization was 
carried with a syringe and needle followed by the addition of 70% ethanol (300 µl) to 
generate appropriate binding conditions of RNA to the RNeasy spin column 
membrane. The homogenates were added onto RNA binding spin columns 
containing silica membranes that selectively bind RNA. After 1 wash using RW1 
buffer and centrifugation at 10.000 rpm for 15 s and 2 washes using RPE buffer and 
centrifugation for 15 s at 10.000 rpm, the isolated RNA was eluted in 35 µl DEPC 
water. RNA concentration was photometric determined by measuring the RNA 
solution at 260 nm in a quartz cuvette using a spectrometer before the integrity was 
analyzed by electrophoresis. Agarose (1.5%) was dissolved in 25 ml ddH2O, boiled in 
a microwave and placed on a magnetic stirrer. 5 ml of 10x MOPS buffer and 4 ml 
formaldehyde was added. Ethidium bromide (EtBr) was dissolved in the mixture to a 
final concentration of 500 ng/ml to visualize the RNA. The gel mixture was poured 
into a gel chamber and cooled until the mass solidified. 200 ng of isolated RNA was 
mixed with 15 µl Loading buffer, heated for 10 min at 68 °C and separated on the gel 
for 1 h at 60 V to prove quantity. RNA samples were visualized on a UV 
transilluminator. cDNA was generated from 1 µg total RNA for further 
semiquantitative PCR analysis. The reverse transcription reaction was performed 
upon DNA wipeout using dDNA buffer. DNA-free RNA was then heated for 2 min at 
42°C before primers, buffer and reverse transcripta se (see Tab.2-5) were added. 
cDNA synthesis was performed for 1h at 42°C. The re action was stopped by 
inactivation of the reverse transcriptase at 94°C f or 5 min. For PCR analysis samples 
were diluted in ddH2O (1:4) (see 2.12). 
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2.12 Polymerase chain reaction 
 
Kit 
FastStart Taq DNA Polymerase Kit Qiagen, Germany 
 
Tab. 2-29 Standard PCR reaction mixture. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Background 
The Polymerase chain reaction (PCR) is a method to amplify copies of a specific 
DNA sequence. A PCR mixture contains the DNA template for amplification, primers 
which bind specifically to sequences present in the DNA fragment, deoxynucleoside 
triphosphates (dNTPs) as basis for new DNA strands, DNA polymerase for 
amplification and a buffer solution to guarantee an environment suitable for DNA 
amplification. PCR is a thermal cycling process which starts with the denaturation of 
the DNA causing double-stranded DNA to separate into two single-stranded DNA 
chains. During the annealing time the primers bind specifically to the DNA. During the 
elongation step the DNA polymerase catalyses the synthesis of new DNA strands by 
adding dNTPs complementary to the template DNA. Standard conditions for 
amplification were varied depending on the size of the amplified DNA fragment. 
 
Protocol 
cDNA was mixed with PCR buffer, dNTPs, Taq DNA polymerase and ddH2O 
according to Tab. 2-29 in a 200 µl PCR reaction tube. PCR reaction was carried out 
in a PCR thermocycler (Tab. 2-30). 
 
 stock 10 µl 
Primer forward 
Primer reverse 
PCR buffer 
dNTPs 
Taq DNA polymerase 
ddH2O 
cDNA 
10 pM 
10 pM 
10x 
10 mM 
       5 U/µl 
 
0.25  µl 
0.25  µl 
1  µl 
0.2  µl 
0.05  µl 
7.5  µl 
100 ng/ml 
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Tab. 2-30 Standard program for DNA amplification. 
 
 
 
 
x35 
 
 
 
 
2.13  Agarose gel electrophoresis 
 
Buffers 
 
Tab. 2-31 Composition of 10x TBE gel buffer, pH 8.0. 
 
Tab. 2-32 Composition of 10x Agarose loading buffer. 
 
 
Reagents 
Agarose    Serva, Germany 
Ethidium bromide solution  
(10 mg/ml)    AppliChem, Germany 
DNA Ladder (100 bp, 1kb)  AppliChem, Germany 
 
Background 
Agarose gel electrophoresis is a method to separate and visualize DNA of different 
size by applying an electric field. Nucleic acid molecules are separated by size since 
the negatively charged DNA migrates through an agarose matrix towards the positive 
electrode. The DNA within the agarose is visualized using Ethidium bromide (EtBr). 
Initial denaturation 
Denaturation 
Annealing 
Elongation 
Final Elongation 
2 min, 95°C 
30 sec, 95°C 
30 sec, 95°C 
1 min , 72°C 
4 min, 72°C  
 MW [g/mol] 1 l [c] 
Tris 
Na2EDTA  
Boric acid 
ddH2O, add to 1l, adjust pH with 1 M HCl 
121.14 
372.2 
61.38 
108 g 
7.45 g 
55 g 
0.9 M 
20 mM 
0.9 M 
 MW [g/mol] stock 30 ml [c] 
Glycerol 
Bromphenol blue 
 
691.94 
85% 
 
20 ml 
0.05 g 
35% 
2.5 mM 
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EtBr is fluorescent dye that intercalates into DNA and the resulting complex is 
detectable using ultraviolet light. 
In this study, agarose gel electrophoresis was used to detect and quantify the 
expression of RT-PCR products (see 3.3/ 3.4 /3.7) of Wisp1, different cell cycle 
markers and migration factors. 
 
Protocol 
PCR samples were diluted in loading buffer, mixed, spun down for a few seconds 
and loaded together with DNA ladder on agarose gels (1-2%). Agarose was 
dissolved in 1x TBE gel buffer, mixed and boiled in a microwave. Ethidium bromide 
was added to a final concentration of 500 ng/ml, the gel solution was poured into gel 
chambers and cooled until it formed a gel. Gel electrophoresis was performed in 1x 
TBE running buffer at 90 V for 30 to 50 min to detect DNA fragments. PCR samples 
were visualized on a UV transilluminator. 
 
 
2.14 Phase contrast and fluorescence microscopy 
Phase contrast and conventional epi-fluorescence images were obtained with a Leica 
IPB microscope equipped with a Leica DC500 camera. For conventional epi-
fluorescent images, excitation was performed with an EQB 100 isolated fluorescent 
lamp. Image acquisition was done with Leica IM50 software. 
 
 
Materials and methods 
 
 41
2.15 Immunofluorescence of FLC4 cells and laser-scanning 
confocal microscopy          
 
Buffers 
 
Tab. 2-33 Composition of 1xPBS buffer. 
 
 
 
 
 
 
 
Tab. 2-34 Composition of Permeabilization solution. 
 
 
 
 
 
 
 
 
Tab. 2-35 Composition of Blocking solution. 
 
 
 
 
 
 
 
Tab. 2-36 Composition of Antibody dilution solution. 
 
 
 
 
 
 
 
Reagents  
 
Histofix (4% PFA)   Roth, Germany 
Draq5®    Alexis Biochemicals, Germany 
DakoCytomation®  
Fluorescent Mounting Medium Dako Cytomation, Germany 
 
 
 1 l 
instamed PBS 
ddH2O, add to 1l 
9.55 g 
 50 ml [c] 
Triton-X-100 
BSA 
1x PBS, add to 50 ml 
0.15 ml 
0.5 g 
0.3%  
1% 
 50 ml [c] 
BSA 
1x PBS, add to 50ml 
0.5 g 1% 
 50 ml [c] 
BSA 
1xPBS, add to 50ml 
0.05 g 0.1% 
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Background 
Immunofluorescent staining is a technique to visualize the distribution of target 
molecules, i.e., proteins (antigens) within a cell by specific fluorescent dyes coupled 
to the specific antibodies that allow formation of antigen-antibody complexes. 
Immunofluorescent staining can further be analysed, e.g., with laser-scanning 
confocal microscopy (LSM), which is an imaging technique that enables the detection 
of fluorescent dyes in thin optical slices. 
In this study immunofluorescent stainings and confocal microscopy techniques were 
performed to investigate expression and localization of E-Cadherin in HCC cell lines. 
 
Protocol 
HCC cells were seeded into 24 well plates (75.000 cells/ well) on glass cover slipes, 
serum starved overnight and followed by respective treatment. To prepare the FLC4 
cells for staining, they were washed two times with PBS and fixed for 10 min at RT 
with 400 µl Histofix solution, followed by permeabilization using 200 µl of Triton-X 
solution for 5 min at RT. After two additional washing steps with PBS, unspecific 
binding of the antibodies was blocked by treating the cells with BSA blocking solution 
for 1 h at RT. After discarding the blocking buffer, primary antibody solutions (see 
Tab.8-2) were applied overnight at 4°C. A second wa shing step was performed the 
next day by using the BSA blocking solution for an additional 20 min, followed by an 
incubation of the cells with secondary antibody solutions (see Tab.8-3) for 3 h at RT. 
Finally, the nuclei were stained with Draq5® for 30 min. Cells were mounted on glass 
slides using DakoCytomation® Fluorescent Mounting Medium and stored at 4°C. 
Confocal images were obtained by a laser spectral confocal microscope with an oil 
objective. The argon laser emitted at 488 nm, the krypton laser emitted at 568 nm 
and the helium/neon laser at 633 nm. The obtained images were acquired with a 
TCS SP2 scanner and the Leica Confocal software (vers.2.5). 
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2.16 Scratch wound healing assay 
 
Background 
The scratch wound healing assay is a method to study cell motility. A scratch, 
simulating an injury within a confluent seeded cell layer is analyzed on an image-
based readout. 
In this study, the scratch wound healing assay was used to determine migratory 
activity of HCC cells upon Wisp1 stimulus. 
 
Protocol 
HCC cell lines (see 2.5.1) were seeded in 6 well plates at a density of 85% and 
allowed to adhere for 5 h. Then, the medium was changed to serum free DMEM 
overnight. At day 1 (100% confluent) the cell layer was injured with a 200 µl pipette 
tip. Immediately after injury, one washing step with HBSS was performed before the 
cells were left either untreated or treated with Wisp1 (100 ng/ml) in 1 ml serum free 
DMEM. Photographs of the scratch area were taken after 4, 6, 8, 10 and 24 h at the 
same position of the wound using a Leica DM IRB Inverted Research Microscope. 
The images were analyzed with Leica QWin Vers.3 software. The area of the scratch 
of each picture was selected manually an the marked area was further determined 
using the area calculator to get the size of the scratch at each timepoint. 
 
 
2.17  HCC in vitro adhesion assay 
 
Background 
With the cell adhesion assay cell contacts between cells and the dish were studied in 
the presence or absence of Wisp1. 
 
Protocol 
Adhesion assays were performed by seeding HCC cells into 6 well plates. The test 
cells were serum starved overnight and then trypsinized for 10 min. The detached 
cells were collected in serum free DMEM medium and sedimented by centrifugation 
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for 12 min at 600 x g using a swing out rotor. The supernatant was discarded, 
whereas the pellet containing the cells was resuspended in 1 ml serum free DMEM 
medium. Then cells (300.000 cells/ml) were either seeded in FCS containing DMEM 
medium (see 2.5.1), serum free DMEM medium or serum free DMEM medium 
containing Wisp1 (100 ng/ml). These cell solutions were plated in duplicates into 6 
well plates. Pictures were taken 30, 60, 90, 120, 150, 180, 210 and 240 min after 
plating on a Leica DM IRB Inverted Research Microscope. The percentage of 
attached cells was obtained by counting the total number of cells and the number of 
cells that had already attached. 
 
 
2.18  Cell proliferation assay  
 
Kits 
BrdU incorporation assay (Cat.No.11647229001) Roche, Germany 
BrdU labelling reagent (5-bromo-2’-deoxyuridine in PBS) 
FixDenat solution 
Anti-BrdU-POD (monoclonal antibody from mouse-mouse hybrid cells, conjugated 
with peroxidase (POD)) 
Antibody-dilution solution 
Washing buffer (10x PBS) 
Substrate solution (TMB, tetramethyl-benzidine)  
 
Reagents 
Mitomycin C   AppliChem, Germany 
 
Background 
The 5-bromo-2’-deoxy-uridine (BrdU) incorporation assay is a method to quantify 
DNA synthesis during cell proliferation. BrdU is a tymidine analog, which can be 
incorporated into the newly synthesized DNA. Following immunodetection via specific 
antibodies the BrdU labelled cells can be visualized. 
In this work, the BrdU incorporation assay was performed to investigate DNA 
synthesis kinetics of HCC cell lines in response to Wisp1 stimulation. 
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Protocol 
The BrdU assay was performed according to manufacturer’s instructions. Cell cycle 
synchronization was induced by serum deprivation for 24 h before the respective 
treatment followed. 2 h before the treatment started, control HCC cells were 
preincubated with mitomycin C (5 µg/ml). Cells then were either treated with serum 
free medium, FCS containing medium, serum free medium containing Wisp1 
(100 ng/ml) or mitomycin C (5 µg/ml). Treatment was carried out for 8 h or 16 h. 2 h 
after the start of treatment 100 µl BrdU labelling substance was added to the culture 
medium. For BrdU staining, the medium was aspirated and the cells were fixed; the 
DNA was denaturated in one step by adding 100 µl FixDenat solution for 1 h at RT. 
Denaturation ensures the accessibility of the incorporated BrdU for further antibody 
detection. Cells were afterwards incubated with the anti-BrdU-antibody (1:100 in 
Antibody Dilution Solution) for 2 h at RT. Cells were then washed 3 times with PBS 
and incubated with 100 µl of the calorimetric substrate for 30 min. The reaction 
product was quantified by measuring the absorbance at 370 nm with a reference 
wavelength of 492 nm using a scanning multi-well spectrometer (ELISA reader). The 
developed blue color of the reaction could be directly correlated to the amount of 
DNA synthesis. Experiments were done in triplicate. Data are presented as an 
average with SD. 
 
 
2.19 Dose response curve and antibiotic selection of HCC 
populations transfected with Puromycin or Neomycin 
 
Reagents 
 
Tab. 2-37 Puromycin stock solution. 
 
 
 
 
 
 
 
 
 100 ml [c] 
Puromycin 
ddH2O, add to 100 ml, sterile 
5 g 50 mg/ml 
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Tab. 2-38 Neomycin stock solution. 
 
. 
 
 
 
Background 
Antibiotic dose response curves determine cell toxicity when they are exposed to 
different concentrations of an antibiotic. Here, Puromycin and Neomycin dose 
response curves were performed to first, determine cell toxicity in HCC cell lines and 
second, to select for cells which contain the resistance gene. 
 
Protocol 
HCC cells (60-80% confluent) were seeded in 24 well plates and on day two exposed 
to a range of concentrations of the respective antibiotics. Viability of cells was 
examined every two days and new DMEM medium containing fresh antibiotics was 
added. Cells were cultured up to 14 days. The lowest concentration of antibiotic that 
killed 100% of the cells in 14 days from the start of antibiotic selection was further 
used (see 2.22) 
 
 
2.20 Bacterial culture 
 
Buffers 
 
Tab. 2-39 Composition of LB (lysogeny broth) medium. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 100 ml [c] 
Neomycin 
ddH2O, add to 100 ml, sterile 
5 g 50 mg/ml 
 1 l 
instamed LB 
ddH2O, add to 1 l, autoclave 
25 g 
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Tab. 2-40 Puromycin stock solution. 
 
 
 
 
 
 
Tab. 2-41 Ampicillin stock solution. 
 
 
 
 
 
 
Reagents 
Agar     Life Technologies, Germany 
LB     Fisher Scientific, Germany 
pLKO.1-puro-CMV-TurboGFP 
TRCN0000033350 and 
TRCN0000033351   Sigma Aldrich, Germany 
pLKO.1-puro UbC-TurboGFP Sigma Aldrich, Germany 
pCMV 891    Sigma Aldrich, Germany 
pMDG    Sigma Aldrich, Germany 
pcDNA3.1+ containing  
full length Wisp1 Kind gift from Dr. M. Young (Department of Health 
& Human Service, Maryland, USA) 
One Shot TOP10 Chemically  
Competent E.coli   Invitrogen, Germany 
 
Background 
Competent cell bacteria can take up a plasmid which includes a foreign gene. 
Further, bacteria containing the plasmid are selected using agar plates containing an 
antibiotic. 
In this study, E.coli bacterial culture was used for the transformation of plasmids 
containing shWisp1 constructs or full-length Wisp1. 
 
 100 ml [c] 
Puromycin 
ddH2O, add to 100 ml, sterile 
5 g 50 mg/ml 
 100 ml [c] 
Ampicillin 
ddH2O, add to 100 ml, sterile  
5 g 50 mg/ml 
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Protocol 
For agar plates, 7.5 g instamed LB and 6 g agar were dissolved in 300 ml ddH2O. 
The solution was autoclaved and then cooled down to 40°C before the antibiotic 
(Puromycin or Ampicillin) was added (60 µg/ml). The solution was poured into Petri 
dishes and allowed to cool at RT for 30 min. Agar plates were closed, sealed with 
parafilm and stored at 4°C. 
Bacteria (50 µl) were thawed on ice for 30 min. 2 µl of plasmid was added onto the 
top of the bacteria and incubated on ice for an additional 30 min. Afterwards, bacteria 
were briefly heat shocked at 42°C for 1 min, transf erred to ice for an additional 5 min 
and mixed with 150 µl 37°C warm LB medium and incub ated at 37°C for 45 min at 
300 rpm. The bacteria solution was plated out on an antibiotic (Puromycin or 
Ampicillin) containing agar plates. The agar plates whereas incubated overnight at 
37°C to allow the bacteria to grow which express th e antibiotic resistant gene. The 
agar plates were stored until further use at 4°C (s ee 2.21). 
 
 
2.21 Plasmid purification 
 
Kit 
EndoFree® Plasmid Purification Kit (Cat.No. 12362)  Qiagen, Germany 
Buffer P1, alkaline buffer 1 
Buffer P2, alkaline buffer 2 
Buffer P3, precipitating buffer 
Buffer QBT, equilibrating buffer 
Buffer QC, washing buffer 
Buffer QN, DNA eluting buffer 
Buffer ER, DNA eluting buffer 
Buffer TE, Tris- EDTA buffer 
Endoxin-free water 
LyseBlue, indicator 
Qiagen syring 
Qiagen column 
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Buffers 
 
Tab. 2-42 Composition of LB (lysogeny broth) medium. 
 
 
 
 
 
Reagents 
Agar  Life Technologies, Germany 
LB  Fisher Scientific, Germany 
Isopropanol Merck, Germany 
 
Background 
Based on the alkaline lysis, plasmid DNA is isolated from bacteria. Bacteria 
containing the plasmid of interest are lysed by a strong alkaline buffer, followed by 
binding of the plasmid DNA to an anion-exchange resin under low-salt conditions. 
RNA, proteins and low molecular weight impurities are removed by a medium-salt 
wash. The plasmid DNA is eluted in a high-salt buffer, concentrated and desalted by 
isopropanol precipitation. 
In this study plasmid purification was used to extract and purify shWisp1 containing 
vectors and full-length Wisp1 containing vectors (see 2.22). 
 
Protocol 
A single colony was picked from an agar plate (see 2.20), placed in 250 ml LB 
medium containing the selective antibiotic and incubated overnight at 37°C with 
shaking at 300 rpm. The next day, the bacterial cells were harvested by 
centrifugation at 6.000 x g for 15 min at 4°C. The bacterial pellet was resuspended in 
25 ml ice cold Buffer P1 containing LyseBlue reagent, an indicator which provides 
optimal buffer mixing. For efficient lysis of the bacteria the buffer was pipetted up and 
down until no clumps were visible. 25 ml of Buffer P2 were added and mixed for 5 
min by inverting the mixture at RT until the cell suspension turned blue. 25 ml of 
chilled P3 Buffer was immediately added to the suspension; fluffy, white material 
appeared containing genomic DNA, proteins and cell debris. The suspension was 
filtrated using the syringe. 2.5 ml of ER Buffer were added to the clear suspension, 
 1 l 
instamed LB 
ddH2O, add to 1 l, autoclave 
25 g 
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inverted and incubated for 30 min on ice. The column was equilibrated by adding 
20 ml of QBT buffer which emptied from the column by gravity. The filtrated lysate 
was added onto the column followed by two washes with 30 ml of QC Buffer. The 
DNA was eluted in 15 ml of QN Buffer and precipitated with 0.7 ml volumes of 
isopropanol. The solution was centrifuged at 15.000 x g for 30 min at 4°C and the 
supernatant decanted. The DNA pellet was washed with 5 ml of endotoxin-free 70% 
ethanol and centrifuged at 15.000 x g for 10 min. The supernatant was decanted and 
the pellet was air-dried for approximately 1h. The DNA was dissolved in 0.5 ml TE 
Buffer. The DNA concentration was determined by spectrometry at 260 nm.  
 
 
 
.
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2.22 Lentivirus production and transfection  
 
Buffers 
 
Tab. 2-43 Composition of Na-butyrate stock solution. 
 
Tab. 2-44 Composition of Poly-D-lysine stock solution. 
 
 
 
 
 
 
Tab. 2-45 Composition of Hexadimethrine bromide stock solution. 
 
 
 
 
 
Reagents 
HBSS    PAA, Germany 
Metafectene   Biontex, Germany  
 
Background 
Lentiviral-based particles permit efficient infection and integration of a specific shRNA 
constructs into differentiated and non-dividing cells. A lentivirus can integrate into the 
host cell genome to allow stable, long-term transgene expression. 
In this work, lentiviral based infection of shRNA against Wisp1 was performed to 
produce transient and stable Wisp1 knockdown cell lines. 
 
 
 
 MW [g/mol] 100 ml [c] 
Na-butyrate 
HBSS, add to 100 ml 
110.09 11 g 1 M 
 10 ml [c] 
Poly-D-lysine 
HBSS, add to 10 ml 
10 g 1 mg/ml 
 5 ml [c] 
Hexadimethrine bromide 
ddH2O, add to 5 ml 
4 g 800 µg /ml 
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Protocol 
For each virus four cell culture dishes were coated with poly-D-lysine solution for 5 
min at RT and then washed with ddH2O for culture of the lentiviral packaging 
Hek293T cells. Per dish 5x106 cells were seeded in 14 ml DMEM (see 2.5.2). 
Hek293T cells were transfected with a transfection cocktail containing 4.4 µg 
lentiviral expression plasmids pLKO.1-puro UbC-TurboGFP and 3.4 µg of packaging 
plasmid pCMV 891 and 2.2 µg pMDG (see. 2.20) using metafectene transfection 
reagent and Na-butyrate to produce lentivirus particles. Lentivirus containing medium 
was concentrated after two days post-transfection using Vivaspin-Tubes according to 
the manufacturer’s instructions. Viral titers were determined by counting GFP-positive 
transfected cells by flow cytometry (see 2.22). Wisp1 silencing cell lines were created 
by adding 0.5, 1 and 2.5 MOI of the respective lentiviruses to the HCC cell lines 
cultured in DMEM medium containing FCS supplied with the transfection reagent 
hexadimethrine bromide (8 µg/ml) for 16 hours. Medium was replaced every day and 
fresh medium with Puromycin (2.5 µg/ml) was added until resistant colonies could be 
identified. Cells were further cultured up to 4 weeks in Puromycin containing medium 
to ensure 100% of transfection efficiency. Wisp1 knockdown was proved by Western 
blot (see 2.8). 
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2.23 Caspase 3 assay 
 
Buffers 
 
Tab. 2-46 Caspase 3 assay stock solutions. 
 
Tab. 2-47 Cell lysate buffer for Caspase 3 assay. 
 
Tab. 2-48 Assay buffer for Caspase 3 assay. 
 
 
 
 
 Stock  100 ml [c] 
HEPES 
NaCl 
CHAPS 
EDTA 
DTT 
Glycerol 
ddH2O, add to 100 ml, adjust pH 7.4 with 1 M 
HCl 
100 mM 
750 mM 
1% 
100 mM 
1 M 
100% 
50 ml 
13.3 ml 
0.1 g 
0.1 ml 
0.1 ml 
10 ml 
50 mM 
100 mM 
0.1% 
100 µM 
1 mM 
10% 
 M [g/mol] 0.5 l [c] 
HEPES 
NaCl 
EDTA 
DTT 
ddH2O, add respectively to 1 l 
238.31 
58.44 
372.2 
154.25 
11.9 g 
21.92 g 
18.61 g 
77.125 g 
100 mM 
750 mM 
100 mM 
1 M 
 Stock  100 ml [c] 
HEPES 
NaCl 
CHAPS 
EDTA 
DTT 
ddH2O, add to 100 ml, adjust pH 7.4 with 1 M 
HCl 
100 mM 
750 mM 
1% 
100 mM 
1 M 
 
50 ml 
13.3 ml 
0.1 g 
0.1 ml 
0.1 ml 
 
50 mM 
100 mM 
0.1% 
100 µM 
1 mM 
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Tab. 2-49 Ac-DeEVD-AFC stock solution, caspase 3 substrate. 
 
Background 
Caspase 3 is an intracellular cysteine protease. It becomes activated during the 
cascade of events which occur during apoptosis. Thereby, caspase 3 cleaves a set of 
cellular molecules which contain the amino acid motif Asp-Glu-Val-Asp (DEVD). 
Thus, cells which are undergoing apoptosis are first lysed and further tested for their 
protease activity by the addition of a caspase-specific peptide which is conjugated to 
a fluorescent reporter molecule, e.g., 7-amino-4-trifluoromethyl coumarin (AFC). The 
cleavage of the peptide by the caspase 3 releases a fluorochrome that emits 
fluorescence light at 505 nm, when excited by light at 400 nm wavelength. The level 
of caspase enzymatic activity in the cell lysate is directly proportional to the 
fluorescence signal detected with a fluorescent microplate reader. 
 
Protocol 
HCC cells were seeded in 24 well plates (75.000 cells/well) in triplicate and serum 
starved overnight. On the next day, proteins were isolated (see. 2.6) in 100 µl 
Caspase 3 cell lysis buffer, followed by determination of protein concentration (see. 
2.7). For the assay, cell lysate, assay buffer and Caspase 3 substrate were pipetted 
into a flat bottom 96 well plate as follows; blank: 90 µl assay buffer, cell lysate: 70 µl 
assay buffer plus 20 µl cell lysate. 10 µl of the substrate (1:20 in assay buffer) were 
added to the blank and cell lysate and the plate was incubated for 6 h at 37°C. ELISA 
measurement of the fluorescence gave the fluorescence signal of each sample. For 
calculation of relative caspase 3 activity, the blank value was subtracted from the 
samples volumes and afterwards normalized to the protein concentration. 
 
 
  
 
 Stock  5 ml [c] 
Ac(N-acetyl)-DEVD (Asp-Glu-Val-Asp)-AFC 
(7-amino-4-trifluoromethylcoumarin) 
DMSO, add to 5 ml 
729.61 
 
5 mg 1.35 mM 
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2.24  Transient overexpression of Wisp1  
 
Buffers 
 
Tab. 2-50 Neomycin stock solution. 
 
Tab. 2-51 Transfection cocktail for HCC cell line.  
 
 
 
 
 
 
 
 
Reagents 
Lipofectamin 2000  Invitrogen, Germany 
Optimem   Invitrogen, Germany 
 
Protocol 
HCC cell lines (60-80% confluent) were seeded into a T25 culture flask. At day two 
they were washed twice with PBS and transfected with 5 µg of plasmid containing the 
full length Wisp1 gene (see. 2.20) using Lipofectamin2000 transfection reagent 
according to the manufacturer’s instruction. After cells remained with transfection 
cocktail for 6 h, they were i) for transient transfection, switched to starvation medium 
for 24 h , followed by protein isolation or ii) for stable transfection, switched to culture 
in full DMEM medium containing Neomycin (800 µg/ml). Medium was changed every 
second day. When Neomycin resistant colonies could be identified, Wisp1 
overexpression was detected by Western blot. Cells were cultured for further 
experiments. 
 
 
 100 ml [c] 
Neomycin 
ddH2O, add to 100 ml, sterile 
5 g 50 mg/ml 
 Each reagent in 100 
ml Optimem 
plasmid 
Lipofectamin2000 
Mix and incubate at  
RT for 20 min 
5 µg 
   4.8 µl 
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2.25  Statistical analysis 
Data are reported as the mean ± SE. To determine if there was significant difference 
within each experiment, we performed Student’s t-test. We considered different 
significance at *p < 0.05 and **p <0.02. All statistical procedures were carried out 
using AIDA Image Analyzer 2.11 software. Experiments were done in duplica or 
triplica. 
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3 Results 
3.1  Wisp1 expression in human HCC samples 
 
To explore possible roles of the Wisp1 protein in human hepatocellular carcinoma, its 
expression was analyzed using Western blot and immunohistochemistry. We found 
that Wisp1 levels were increased, decreased or not changed when comparing normal 
tissue (N) adjacent to a liver tumor and tumor (T) tissue samples (Fig.3-1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3-1 Western blot analysis of Wisp1 in normal (N) liver adjacent to tumor (T) samples. (A) A 
single band corresponding to the predicted MW of Wisp1 was identified at 48 kDa using an anti-
human Wisp1 specific antibody. To demonstrate equal protein loading of the gel, b-actin was detected 
as a reference in the same samples. (B) Quantification of the immunoblot signal of different intensities 
was normalized to the reference protein b-actin. Data are presented as the mean. Error bars on data 
points represent SE of the mean. 
 
In the next step, to explore the tissue expression pattern and localization of Wisp1 in 
healthy versus hepatocellular carcinoma samples, 48 liver biopsies from HBV-
positive HCC patients were analyzed by immunohistochemistry using Wisp1 specific 
antibodies. Clinicopathological data are summarized in Tab.3-1. 
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B. Clinicopathological data Number
Total
Gender
M
F                 
Child-Pugh stage
A
B,C
10
8
2
10
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Tab. 3-1 Clinicopathological data of 48 HBV infected patients with liver cancer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinicopathological data Number 
Total 
Gender 
M 
F 
Age 
>50 
≤50 
Tumor number 
single 
multiple 
Tumor size (cm) 
>5 
≤5 
unknown 
Depth of invasion 
T1,2 
T3,4 
unknown 
Child-pugh class 
A 
B,C 
not classified 
Nodal stage 
N0, 1 
N2, 3 
Differentiation grade 
well 
moderate 
poor 
48 
 
43 
5 
 
25 
23 
 
38 
10 
 
23 
20 
5 
 
20 
23 
5 
 
24 
19 
6 
 
48 
0 
 
6 
22 
20 
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In normal adjacent liver sections, in “healthy” areas fulfilling the main criteria of 
morphologically non-injuired hepatocytes, Wisp1 was either absent or weak staining 
was found in the cytoplasm (Fig.3-2A). In normal adjacent liver sections, areas with 
damaged hepatocytes and multifocal inflammation, represented by an accumulation 
of lymphocytes, showed a strong positive signal for Wisp1 in hepatocytes in close 
proximity to the areas of inflammation (Fig.3-2B). Furthermore, hepatic steatosis was 
present in some patients with HBV-induced liver cancer. In the non-tumorigenic area 
of these patients, strong Wisp1 expression was found in hepatocytes surrounding fat 
droplets (Fig.3-2C). 
 
Fig.3-2 Representative pictures of Wisp1 immunohistochemical staining in non-tumorigenic 
areas of patients with liver cancer (A) No Wisp1 staining in healthy HCs. (B) Strong Wisp1 staining 
in HCs surrounding the areas of inflammation indicated by the red arrow. (C) Strong Wisp1 signals are 
present in section with hepatic steatosis in cells surrounding fat droplets indicated by the green arrow. 
(D) No staining was detectable under control conditions in 4 liver sections when the primary antibody 
was omitted. The magnifications are indicated by scale bars. 
 
A. Healthy hepatocytes B. Inflamed areas
C. Steatotic areas D. Control, 2nd antibody
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Interestingly, the intensity of Wisp1 signals in liver sections evaluated as tumor 
regions correlated negatively with the cancer stage of the tumor. In patients with well 
differentiated hepatocellular carcinoma, strong Wisp1 expression was found in 
hepatocytes of the tumor. Wisp1 expression was not found in HCs nuclei, endothelial 
cells of vessels or cholangiocytes of the bile ducts (Fig.3-3A). In patients with 
moderately differentiated HCC, immunohistochemical staining for Wisp1 showed 
moderate to low expression of the protein in hepatocytes of the tumor area (Fig.3-
3B). In poorly differentiated HCC, Wisp1 expression was not found (Fig.3-3C). 
 
Fig.3-3 Representative pictures of Wisp1 immunohistochemical staining in the tumor area of 
patients with liver cancer. (A) Strong Wisp1 positive staining (in brown) in HCs of the tumor region of 
well differentiated HCC. (B) Moderate to low positive staining in HCs of the tumor region of moderately 
differentiated HCC. (C) Wisp1 was not present in HCs of the tumor region of poorly differentiated 
HCC. Nuclei are counter-stained in blue by hematoxylin. The magnifications are indicated by scale 
bars. 
 
A. Well differentiated B. Moderately differentiated
C. Poorly differentiated
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However, in patient samples with advanced-stage HCC, Wisp1 staining was 
detectable in multinicleated hepatocytes (Fig.3-4A) and the tumor stroma (Fig.3-4B). 
 
A.  Multinucleated cancer cells B. Stroma
 
 
Fig.3-4 Representative picture of Wisp1 immunohistochemical staining from the tumor area of 
patients of poorly differentiated HCC. Strong positive staining (brown) in multinicleated cancer cells 
indicated by yellow arrow and (B) in the stroma indicated by green arrow. Nuclei are counter-stained in 
blue by hematoxylin.The magnification is indicated by scale bars. 
 
 
Taken together, immunohistochemical staining data (Tab.3-2) revealed that in well 
differentiated HCC, Wisp1 expression was strong in 83% of patients (5 out of 6 
patients). In moderately differentiated HCC, Wisp1 expression was weak to moderate 
in 82% of patients (18 out of 22 patients). Furthermore, in poorly differentiated HCC, 
Wisp1 expression was weak in only 30% of patients (6 out of 20 patients). 
 
Tab. 3-2 Wisp1 expression level in tumor region of 48 HBV-positive infected patients with HCC. 
Wisp1 expression level: 0 no, + weak, ++ moderate, +++ strong. 
 
Table 3-3 gives a detailed overview of Wisp1 expression and its precise localization 
in liver cancer of 48 patients. Normal liver tissue adjacent to tumors and tumor 
samples for each patient are shown. 
Differentiation 
grade 
Total no. of 
samples 
0 + ++ +++ 
well 
moderate 
poor 
6 
22 
20 
 
2 
12 
 
10 
6 
1 
8 
1 
5 
2 
1 
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Tab. 3-3 Wisp1 expression in 48 patients with liver cancer.  
Wisp1 expression level: 0 no, + weak, ++ moderate, +++ strong 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No. of sample Non-tumor Wisp1 levels Characteristics of non-
tumor areas 
Tumor Wisp1 levels Differentiation grade 
1 +++ positive damaged HCs 0 poor 
2 +++ positive damaged HCs/ 
hypertrophic HCs 
+ moderate 
3 +++ positive damaged HCs, 
negative multinicleated 
HCs  
+ moderate 
4 +++ positive damaged HCs/ 
multinicleated  HCs 
+ moderate 
5 +++ positive steatotic areas ++ moderate 
6 +++ positive multinicleated  
HCs 
++ moderate 
7 ++ positive damaged HCs 0 moderate  
8 ++ positive inflamed areas 0 poor 
9 ++ positive steatotic 
areas/stroma  
0 moderate 
10 ++ positive stroma 0 poor 
11 ++ positive damaged HCs 0 poor 
12 ++ positive steatotic areas + poor 
13 ++ positive steatotic areas + moderate 
14 ++ positive multinicleated  
HCs 
+ moderate 
15 + healthy 0 poor 
16 + positive multinicleated  
HCs 
0 poor 
17 + healthy  0 poor 
18 + healthy 0 poor 
19 0 healthy 0 poor 
20 0 healthy 0 poor 
21 0 healthy 0 poor 
22 0 healthy 0 poor 
23 0 healthy 0 poor 
Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No. of sample     non-tumor Wisp1 
               levels 
characteristics of non-
tumor areas 
tumor Wisp1 levels Differentiation grade 
24 + healthy + poor 
25 + healthy + moderate 
26 + positive steatotic areas + moderate 
27 + positive stroma + poor 
28 + positive steatotic areas + moderate 
29 + positive multinicleated  
HCs 
+ poor 
30 + healthy + moderate 
31 ++ healthy ++ moderate 
32 +++ positive damaged HCs +++ moderate 
33 +++ healthy +++ well 
34 +++ positive damaged HCs +++ well 
35 +++ positive damaged HCs +++ well 
36 0 healthy + poor 
37 0 healthy + poor 
38 0 healthy ++ moderate 
39 0 healthy ++ moderate 
40 0 healthy ++ moderate 
41 + positive stroma ++ well 
42 + positive steatotic areas ++ poor 
43 + positive steatotic areas ++ moderate 
44 + positive HCs/ stroma ++ moderate 
45 ++ positive multinicleated HCs +++ moderate 
46 ++ positive HCs/ steatotic 
areas 
+++ poor 
47 ++ positive HCs, negative 
steatotic area 
+++ well 
48 ++ positive HCs/ 
multinicleated HCs 
+++ well 
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Furthermore, we found specific Wisp1 expression patterns in the peripheral and 
central part of HCC. Figure 3-5A shows the characteristic histological pattern of the 
central and peripheral parts of HCC. Marked hepatocellular necrosis is present in the 
central part. Rich microvessels can be seen in the peripheral part. Figure 3-5B shows 
the suitable Wisp1 expression pattern in these different regions. Weak (yellow) or no 
Wisp1 positive staining was detected in the central part. Moderate to strong (brown) 
Wisp1 positive expression was found in the peripheral part. Wisp1 expression in the 
periphery of HCC suggests involvement of Wisp1 in tumor growth and migration. 
 
 
 
  
 
 
 
 
 
 
 
 
 
A.                    Central                                              Periphery
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B.                    Central                                              Periphery
 
 
 
Fig.3-5 Characteristic histological pattern of the central and peripheral parts of HCC. (A) 
Hematoxylin staining for nuclei, eosin staining for cytoplasm. Yellow arrows indicate necrotic areas 
and rich microvessels. (B) Wisp1 weak (yellow) or no staining was detected in the central part. Wisp1 
moderate to strong expression (brown) was found in the peripheral part. Nuclei are counter-stained in 
blue by hematoxylin. 
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3.2 Positive correlation between Wisp1 and E-Cadherin 
expression in human HCC samples 
 
Since E-Cadherin plays a key role in the establishment and maintenance of 
intracellular adhesions and tissue architecture, and as alterations in E-Cadherin 
expression are associated with dedifferentiation, invasiveness, lymph node and 
distant metastasis in primary HCC [71, 72], we analyzed human HCC patient 
samples with immunohistochemistry for E-Cadherin expression and correlated the 
data to our findings of Wisp1 expression in HCC.  With immunohistochemical staining 
of the various differentiation grades, we found strong membranous expression of 
endogenous E-Cadherin only in well differentiated HCC (Fig.3-6A). In moderately 
differentiated HCC, E-Cadherin expression was low, detected by positive brown 
staining at the membrane and in the cytoplasm of HCs (Fig.3-6B). E-Cadherin 
expression was not found in poorly differentiated HCC (Fig.3-6C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3-6 Representative pictures of E-Cadherin immunohistochemical staining in the tumor area 
of patients with liver cancer. (A) Strong E-Cadherin positive staining (in brown) at the cell 
membrane of cancer cells of well differentiated HCC. (B) Moderate to low positive staining at the cell 
membrane and cytoplasm of cancer cells of the tumor region of moderately differentiated HCC. (C) E-
Cadherin was not present in the tumor region of poorly differentiated HCC. Nuclei are counter-stained 
in blue by hematoxylin. 
A. Well differentiated B. Moderately differentiated
C. Poorly differentiated
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Comparison of Wisp1 and E-Cadherin expression intensity in HCC patient samples 
showed a positive correlation (Fig.3-7). The strong Wisp1 positive cases of early-
stage HCC (median 3) also showed strong E-Cadherin staining (median 3). The low 
Wisp1 positive cases of intermediate-stage HCC (median 1) were accompanied by 
moderate E-Cadherin staining (median 2). There was no Wisp1 expression in 
advanced-stage HCC, but low E-Cadherin expression (median 1) was shown.  
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Fig. 3-7 Comparison of Wisp1 and E-Cadherin expression in human HCC patient samples.  
 
Taken together, these findings show that decreased Wisp1 expression correlates 
positively with decreased E-Cadherin expression. As loss of E-Cadherin expression 
is a main characteristic of malignant cells, we assume further in our in vitro analysis 
that Wisp1 action depends on E-Cadherin. 
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3.3 Epithelial and fibroblastoid-type HCC cell lines produce 
and secrete Wisp1 
 
Since HCC is a very heterogenous disease we anticipated that the tumorigenesis of 
particular subtypes might depend on Wisp1 induction. To gain insight into the 
functional significance of Wisp1 up-regulation in early-stage HCC, we studied two 
different human HCC derived cell lines (Fig.3-8). FLC4 cells are characterized by 
albumin secretion [67]. In addition, FLC4 cells show a polygonal-shaped morphology, 
are able to form bile canaliculi and express high levels of E-Cadherin, all together, 
representing an epithelial phenotype with well-preserved liver function. In contrast, 
HLF cells show fibroblast-like phenotypes and do not secrete albumin [69]. Both cell 
lines represent well established in vitro systems for the analysis of human HCC [66]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3-8 Typical features of FLC4 and HLF cell lines. (A) Morphological criteria of epithelial FLC4 
and fibroblast-like HLF cells. Representative pictures were taken by light microscopy (objective x10) 
one day after plating of the respective cells. (B) Immunofluorescence pictures showing E-Cadherin 
(green) and nuclei (blue) in FLC4 and HLF cells. (C) Immunoblot analysis of E-Cadherin in FLC4 and 
HLF lysates. Gapdh was used as a loading control.  
FLC4 HLFA.
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To determine whether Wisp1 is expressed in HCC cell lines, immunoblots of total 
protein isolated from FLC4 and HLF cells were performed. Wisp1 was detectable in 
both cell lines (Fig.3-9A). Since it has been suggested that Wisp1 is a secreted 
protein [51], the amount of Wisp1 released by FLC4 and HLF cells to the culture 
medium was determined. Cell-conditioned media was collected at days 1, 2 and 3. 
Proteins were precipitated with acetone and analyzed by immunoblots using Wisp1 
specific antibody. By day 3, the Wisp1 protein was detected in the conditioned 
medium of both cell lines (Fig.3-9B). It is tempting to speculate that secreted Wisp1 
can stimulate cells by autocrine/paracrine signaling. To test this hypothesis, the 
effects of recombinant human Wisp1 and knockdown was tested in vitro on different 
parameters including cell growth and motility (Fig.3-9C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3-9 HCC cells express and secret  Wisp1. (A) FLC4 and HLF cell lines were cultured for 1, 2 
and 3 days. 35 ug of total protein lystates were separated on a 12% SDS PAGE gel and then 
immunoblotted. Wisp1 and actin, as a loading control, were detected by the use of specific antibodies 
in the same lysates. (B) Secreted proteins were precipitated with acetone from cell conditioned media 
followed by separation on SDS PAGE and immunoblot (for further details on the precipitation method 
please consult the materials and methods section). (C) Wisp1 depletion in FLC4 cells. Wisp1 protein 
and RNA levels were decreased in FLC4 cells using shRNAs targeting Wisp1. Cells were transiently 
transfected with 1.5 MOI only with shRNA control (shco) or shRNAs for Wisp1 (sh0 and sh1). 
Endogenous Wisp1 was detected from total protein and RNA lysates. 
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3.4 Regulation of cell-cycle by Wisp1 in HCC cells 
 
Since it has been shown earlier that the Wisp1 pathway is involved in cell growth, 
motility, transformation and survival of cells [50, 62, 73, 74], changes in these 
parameters were investigated in HCC cells upon Wisp1 stimulation or inactivation. 
Cell growth was arrested by serum deprivation followed by BrdU incorporation and 
treatment of the cultures with recombinant human Wisp1. To determine whether 
Wisp1 stimulation affects the growth kinetics of the HCC cell lines, we determined the 
incorporation at different time points. Wisp1 treatment significantly increased BrdU 
incorporation of FLC4 cells, whereas the same Wisp1 concentration had no effect on 
the fibroblast-like HLF cells (Fig.3-10). In the same set of experiments, no changes 
were detectable between the two cell lines regarding their response to a FCS-
dependent stimulation of growth or growth arrest induced by mitomycin C treatment. 
These results indicate that the general growth properties of FLC4 and HLF cells are 
comparable, whereas the response to Wisp1 stimulation depends on the specific 
phenotype of the cell. Furthermore, BrdU incorporation in Wisp1 depleted FLC4 cells 
was significantly reduced in comparison to control cells transfected with control virus 
(Fig.3-10C). In comparison to PBS treatment, FCS did not stimulate BrdU 
incorporation in Wisp1 depleted HCC cells. Wisp1 depleted cells were insensitive to 
mitomycin C dependent blocking of DNA synthesis, whereas DNA blocking induced 
by mitomycin C was evident in all experiments analyzing untransfected or control 
transfected cells. These findings were corroborated by Western blot analysis 
revealing reduced protein levels of the proliferation marker PCNA upon Wisp1 
knockdown (Fig. 3-10D). 
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Fig.3-10 Wisp1 affects FLC4 proliferation response and has no effect on HLF cells. (A) FLC4 
and (B) HLF cell lines were either treated for 8h or 16h with Wisp1 (100 ng/ml), PBS (vehicle), FCS or 
mitomycin C (5 µg/ml). Proliferation was analyzed by the BrdU incorporation assay. (C) Wisp1 knock-
down attenuates proliferation of FLC4 cells. Again, FLC4 cells transfected with 1.5 MOI control hairpin 
vector (shco) and shRNA targeting Wisp1 (sh0/sh1) were either treated with PBS (vehicle), FCS 
(positive control) or mitomycin C (5 µg/ml, negative control). Proliferation was measured by the BrdU 
incorporation assay. (D) Immunoblot analysis for PCNA. Tubulin was used as a loading control. (E) 
Quantification of signal intensities representing gene expression was normalized against tubulin. Data 
are presented as the mean of 2 experiments. Error bars represent SE. 
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To further support these findings, additional HCC cell lines including epithelial-type 
Hep3B [75] and fibroblast-type HCC-T cells [76] were stimulated with Wisp1 followed 
by the BrdU incorporation assay. Wisp1 effects on Hep3B and HCC-T cells were 
similar to the previous results using FLC4 and HLF cells, and thus dependent on the 
HCC cell phenotype (Fig.3-11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3-11 Wisp1 increases the proliferation of Hep3B but not of HCC-T cells. (A) HCC cell lines 
were either treated for 8h and 16h with Wisp1 (100 ng/ml), PBS (vehicle), FCS (positive control) or 
mitomycin C (5 µg/ml, negative control) and then proliferation was analyzed using a BrdU 
incorporation assay. (B) Immunoblot analysis of E-Cadherin in Hep3B and HCC-T lysates. B-actin was 
used as a loading control. 
 
 
Next, we analyzed the expression of marker genes during cell cycle progression 
± Wisp1 treatment (Fig.3-12). HCC cell lines were left either untreated or were 
stimulated for 24 h with recombinant human Wisp1 (100 ng/ml) and mRNA levels of 
the different marker genes were assessed using a semi-quantitative RT-PCR 
method. In line with the BrdU data, Wisp1 did not change the cyclin expression levels 
in the HLF cell line), but induced the expression of early cyclinD1 more than 1.5 fold 
and of cyclinE1 more than 2 fold in the FLC4 cell line (Fig.3-12A/B). In addition, we 
analyzed effects of Wisp1 silencing on expression of cell cycle markers. Wisp1 
knockdown in FLC4 cells resulted in an almost complete ablation of the early 
cyclinD1, whereas cyclinA2 expression levels were significantly reduced by more 
than 50% as compared to untransfected cells (Fig.3-12C/D).  
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Fig.3-12 Wisp1 effects proliferation of FLC4 but not of HLF cells. (A) Total RNA was extracted 
from FLC4 and HLF cell lines using the RNeasy kit according to the manufacturer’s instructions. 
Semiquantitative RT-PCR analysis demonstrates the response of cell cycle markers (cyclins) to 24 h 
Wisp1 stimulation. (B) Cyclin expression was quantified against beta-actin using AIDA Image Analyzer 
2.11 software. Data are presented as the mean ± SE. (C) Expression of cell cycle markers in Wisp1 
depleted FLC4 cells. A representative semi-quantitative RT-PCR analysis of untransfected (-) control 
transfected (shco) and Wisp1 knockdown cells (sh0/sh1) is shown. (D) Quantification of signal 
intensities representing gene expression levels. Cyclin expression was normalized against beta-actin. 
Data are presented as the mean. Error bars represent SE. 
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To test whether overexpression of Wisp1 would mimic the effects of exogenous 
Wisp1 treatment, both cell lines were transiently transfected using a mammalian 
Wisp1 expression vector. In FLC4 cells, but not in HLF cells, Wisp1 overexpression 
increased DNA synthesis and PCNA protein levels in comparison to control 
transfections using an empty vector (Fig.3-13). Together, these results suggest that 
Wisp1 stimulates the proliferation of epithelial FLC4 cells, but does not change the 
growth properties of the fibroblast-like HCC cell line HLF. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3-13 Wisp1 overexpression increases proliferation of FLC4 but does not affect the HLF cell 
line. (A) HCC cell lines were transiently transfected using 1 µg control plasmid DNA or plasmid 
containing a Wisp1 expression cassette. 30 h after transfection, protein lysates were harvested and 
analyzed by immunoblot using Wisp1 specific antibodies. The Wisp1 overexpressing cells were further 
analyzed for changes in PCNA protein levels and (B) the effects on DNA synthesis by BrdU 
incorporation. 
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3.5 Mitogenic effects of Wisp1 depend on E-Cadherin 
 
It is well-known that FLC4 cells, in contrast to HLF cells, express high levels of the 
epithelial-cadherin (E-Cadherin). In addition, it was reported that interactions of CCN 
members with cadherins modulate signaling pathways [41, 77, 78]. To investigate 
whether the response of FLC4 cells to Wisp1 depends on E-Cadherin, we examined 
the effect of Wisp1 on proliferation and cell cycle progression upon E-Cadherin 
depletion. We found, that the E-Cadherin knockdown largely abolished the Wisp1 
mediated proliferative response of FLC4 cells (Fig.3-14B). These results could be 
reproduced by the use of four different siRNAs specifically targeting different parts of 
the E-Cadherin mRNA, whereas a scrambled siRNA oligo had no effect (Fig.3-14A). 
Importantly, the depletion of E-Cadherin did not affect BrdU incorporation to FLC4 
cells per se. These data suggest that E-Cadherins are important for Wisp1 
dependent effects in epithelial-type HCC cell lines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3-14 Knockdown of E-Cadherin decreases Wisp1-dependent proliferation of FLC4 cells.
(A and B). FLC4 cells were transfected with control (siCon) or specific siRNA targeting E-Cadherin 
mRNA (siE1-siE4). 48 h later, the cells were treated with Wisp1 (100 ng/ml), PBS (vehicle), FCS 
(positive control) or mitomycin C (negative control) for an additional 16 h and then analyzed for 
proliferation by the BrdU incorporation assay. Data are normalized against PBS. Data are presented 
as the mean. Error bars represent SE. 
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3.6 Wisp1 activates multiple signaling pathways in  
epithelial and fibroblast-like HCC cell lines 
 
Since binding of CCN proteins via their thrombospondin domain to integrins was 
reportedly detected [41, 44, 79], we analyzed the activation of kinases which mediate 
cellular effects downstream of integrins including cell proliferation, migration and 
survival. Immunoblot with phospho-specific antibodies demonstrated a rapid 
phosphorylation of Fak (Tyr-397), Src (Tyr-416), Akt (Ser-473) and Erk1/2 (Typ-204) 
in both HCC cell lines upon Wisp1 treatment (Fig.3-15A). Fak and Src activation were 
detected only after 15 min of Wisp1 stimulation, while Akt and Erk1/2 phosphorylation 
were detected after 30 min of stimulation. Immunoblot analysis revealed that the 
respective total protein kinase levels were not changed by Wisp1. Other kinases, like 
p38 and cJun, were not activated by Wisp1. These data show that Wisp1 activates 
Fak, Src, Akt and Erk1/2 in both epithelial- (FLC4) and fibroblast-like (HLF) HCC cell 
lines. To determine which signaling pathways are affected by Wisp1 silencing in 
FLC4 cells, we performed immunoblots using phospho-Fak, -Src, -Akt and -Erk1/2 
antibodies and antibodies for total protein detection (Fig.3-15C). Wisp1 knockdown in 
the FLC4 cells caused a decrease in pFak and pErk1/2, whereas Fak and Erk1/2 
levels were unaffected. Phospho-Akt protein level was not altered upon Wisp1 
knockdown, but pAkt protein level was decreased. Src protein expression was lower 
than in untransfected cells and, consequently, pSrc level was also decreased.  
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Fig.3-15 Wisp1 induced changes in integrin-dependent signaling pathways. (A) Representative 
immunoblot analysis of phospho-Fak (Tyr-397), phospho-Src (Tyr-416), phospho-Akt (Ser-473), 
phospho-Erk1/2 (Tyr-204), phospho-p38 (Thr-180/Tyr-182), phospho-c-Jun (Ser-63) and the 
respective un-phosphorylated proteins from FLC4 and HLF cell lysates treated ±Wisp1 (100 ng/ml). 
(B) Quantification of the immunoblot signal intensities was normalized to the reference protein 
GAPDH. Data are presented as the mean of 2 independent experiments. Error bars on data points 
represent SE of the mean. (C) Signal transduction in FLC4 Wisp1 knockdown cell lines. Again, FLC4 
cells were transfected with 1.5 MOI control hairpin vector (shco) and shRNA targeting Wisp1 
(sh0/sh1). Immunoblot analyses of phospho-Fak (Tyr-397), phospho-Src (Tyr-416), phospho-Akt (Ser-
473), phospho-Erk1/2 (Tyr-204) and the respective un-phosphorylated proteins. 
 
 
 
3.7 Wisp1 increases the migration of fibroblast-like HCC 
cells 
 
Metastasis formation refers to the spread of cancer in the body involving malignant 
cells that exhibit increased migration ability. It has been suggested that integrins and 
Wisp1 [47] can modulate the mobility of cancer cells. As we found, Wisp1 activates 
multiple kinases (Fig.3-15) in the HLF cell line which do not lead to an increase in 
proliferation (Fig.3-8), therefore, we compared the migration ability of Wisp1 
stimulated and untreated HLF cells by the scratch wound-healing assay. Scratch 
coverage by HLF cells was increased upon Wisp1 treatment (Fig.3-16A and B). 
Directed migration depends on the formation of new adhesions, which promote cell 
attachment. Interestingly, in the presence of Wisp1, the attachment of HLF cells to 
the cultured dish was faster (Fig.3-16C). Furthermore, it has been reported that CCN 
members have an effect on multiple MMPs (Metalloproteinases) and their inhibitors 
TIMPs (Tissue Inhibitors of Metalloproteinases) which play a key role in migration 
[80-82]. We found that Wisp1 stimulation downregulated TIMP1 expression in the 
HLF cell line. 
Taken together, the migration and adhesion assays demonstrate increased cell 
motility upon Wisp1 treatment indicating that secretion of Wisp1 by HCC might 
promote tumor growth and metastasis. In addition, it is possible that solid tumors fine-
tune their microenvironment via Wisp1 secretion to differentially regulate growth 
and/or migration. 
 
 
 
Results 
 
80 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.3-16 Wisp1 increases the migration rate of HLF cells. (A and B) In vitro scratch wound healing 
assay of HLF cells. Panels show representative images (5x objective) of untreated and Wisp1 
stimulated cells at day 1 (immediately after injury) for baseline measurements and again at 24 h upon 
scratching and ±Wisp1 (100 ng/ml) stimulation. (B) Quantitative representation of results in A. Data 
were calculated on the basis of 3 independent experiments. Data are presented as the mean. Error 
bars represent SE. (C) Cell attachment of HLF cells in the cell adhesion assay. The data was collected 
after 30 min to 4 h after plating, n = 3, in triplicates. Data are presented as the mean. Error bars 
represent SE. (D) Total RNA was extracted from the HLF cell line using the RNeasy kit according to 
the manufacturer’s instructions. The semiquantitative RT-PCR analysis demonstrates the response of 
TIMP1 and TIMP2 to 24 h of Wisp1 stimulation. (E) TIMP expression was quantified against beta-actin 
using AIDA Image Analyzer 2.11 software. Data are presented as the mean ± SE. 
 
 
 
3.8 Apoptotic cell death is induced by Wisp1 inhibition in 
HCC cell lines  
 
Inactivation of apoptosis, programmed cell death, is a hallmark of cancer progression 
[83]. Inactivation of the apoptotic response of cancer cells contributes to their 
resistance against cancer treatments [83]. Understanding of pro-and anti-apoptotic 
proteins would help to predict cancer treatment options. Evidence exists that CCN 
proteins regulate cell survival and show pro- or anti-apoptotic effects [54, 84, 85]. 
0h 24h
control
Wisp1
60
80
100
1                       2                       3                      4
time after plating (h)
%
 
o
f a
tta
c
he
d 
c
e
lls Wisp1
control
A. B.
C. D. E.
0
5
10
15
20
25
0 5 10 15 20 25
time after scratch (h)
%
 
s
c
ra
tc
h 
c
o
v
e
ra
ge Wisp1
control
TIMP1
TIMP2
b-actin
- +
HLF
Wisp1
ar
b.
u
n
its
, 
fo
ld
 
c
hn
a
ge
TIMP2
a
rb
.
u
n
its
, 
fo
ld
 
c
hn
ag
e
0
0.5
1
Control             Wisp1
0
0.5
1
Control             Wisp1
TIMP1
Results 
 
81 
 
Therefore, apoptosis was studied in Wisp1 control and knockdown HCC cell lines. 
Caspase 3 activity assays revealed that Wisp1 depletion by shRNAs results in an 
increase in FLC4 cell apoptosis (Fig.3-17A), whereas Wisp1 treatment of Wisp1 
depleted cells reduced Caspase 3 activity. Furthermore, the anti-apoptotic protein 
BCL-XL is known to regulate cell death by inhibiting caspase activation and, 
consistently, immunoblot analysis showed a decrease in protein level of the anti-
apoptotic marker BCL-XL (Fig.3-17B). Higher MOI of virus infection resulted in 
complete cell death after 2 weeks in the shWisp1 infected FLC4 cells while control 
transfected cells survived. Indeed, we suggest that Wisp1 is important for the survival 
of cancer cells. 
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Fig.3-17 Effects of Wisp1 knockdown on FLC4 cell apoptosis. (A). Caspase 3 enzymatic activity 
assay in untransfected FLC4 cells, with 1.5 MOI control transfected cells (shco) and Wisp1 knockdown 
cells (sh0/sh1). (B) Immunoblot analysis for BCL-XL and loading control tubulin. Quantification of 
signal intensity representing gene expression was normalized against tubulin. Data are presented as 
the mean. Error bars represent SE. (C) Light microscopy and fluorescence microscopy pictures of 
FLC4 cells which were transiently transfected with 5 MOI shRNA control (shco) or shRNAs to Wisp1 
(sh0 and sh1). Cells were cultured up to 2 weeks before they died in culture. 
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4 Discussion 
The aim of the present study was to elucidate whether the matricellular CCN protein 
Wisp1 is associated with the development of hepatocellular carcinoma in humans 
and to investigate the mechanisms of Wisp1 function in HCC and HCC-derived cell 
lines.  We provide evidence that Wisp1 is up-regulated in cancer cells found in well 
differentiated hepatocellular carcinoma. Using different approaches, we also found 
that the proliferation of epithelial-type cancer cells and the migration of fibroblast-like 
cancer cells depend on functional Wisp1 indicating that Wips1 is a potential 
biomarker and involved in tumor progression. These results are of interest since HCC 
exhibits a poor prognosis due to currently insufficient therapies and new diagnostic 
markers for the early detection of the disease or novel targets for therapy are highly 
desired. Unfortunately, early HCC lacks the typical characteristics of advanced HCC 
including an increase in the common tumor markers α-fetoprotein, (AFP) etc. or 
histological alterations [76]. Thus, HCC usually is first diagnosed in patient when liver 
cirrhosis [86, 87] is established and HCC had advanced to treatment resistant stages 
[73].  
 
 
Expression and localization of Wisp1 in liver biopsies of patients 
with hepatocellular carcinoma  
 
Very recently, other groups reported altered levels of Wisp1 expression in different 
cancer entities [50, 74] and associated them with the malignancy of the disease [50, 
62]. To our knowledge, the present study is the first attempt towards a 
comprehensive analysis of the CCN protein Wisp1 in HCC. It was hypothesized that 
Wisp1 could be used as an immunohistochemical marker for HCC staging. To 
investigate the expression pattern and localization of Wisp1 in hepatocellular 
carcinoma we stained 48 HCC patient samples together with normal adjacent liver 
tissue from the same individuals (Tab.3-1).  First, the immunohistochemical study 
shows that Wisp1 is very specific for hepatocytes. Second, our results indicate for the 
first time that  uninjured hepatocytes were negative for Wisp1 or showed only a low 
Wisp1 signal (Fig.3-2). In contrast, increased Wisp1 expression was observed in 
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damaged hepatocytes surrounding focal areas of inflammation and in hepatocytes 
with multi nuclei, as well as in cancerogenous hepatocytes of patients with well to 
moderately differentiated HCC (Fig.3-3/3-4). In contrast, poorly differentiated HCC 
Wisp1 expression was not found. Hence, when damaged hepatocytes are 
transformed they express higher levels of Wisp1, whereas Wisp1 expression is lost 
again in advanced stages of the tumor. These findings, in particular in regard to the 
overexpression of Wisp1 during inflammation of well differentiated cancer, suggests 
that Wisp1 expression may be valuable as a useful bio-marker for the early diagnosis 
of HCC, as well differentiated histology is exclusively seen at early stages and is rare 
in advanced HCC. These data also suggest a dual role of Wisp1 in HCC, depending 
on the differentiation stage. Published data already indicate a close association of
b-catenin mutations and Wnt signaling with a low tumor stage [88]. Our findings also 
indicate that Wisp1 is located in the tumor stroma (Fig.3-4) suggesting that binding of 
Wisp1 to collagen is via its TSP-1 and other CCN domains [89, 90]. Binding of CCN 
proteins to ECM components such as fibronectin or collagen has been reported [91-
93] and mutated TSP domains in CCN have been linked to different types of tumors 
[33, 94]. In addition, diffuse fatty changes of well differentiated tumor cells are often 
investigated in HCC. Interestingly, steatotic regions of fatty livers were also positive 
for Wisp1 (Fig.3-2). Wisp1 was recently shown to be associated with marked 
attenuation of lung fibrosis, including decreased collagen deposition, suggesting that 
functional Wisp1 antagonists are of therapeutic value for fibrotic lung diseases [74]. 
In neoplastic diseases, Wisp1 expression levels were associated with lymphatic and 
perineural invasion of tumor cells, as well as a poor clinical prognosis in 
cholangiocarcinoma [59]. In breast cancer, Wisp1 expression was correlated with 
tumor size, staging, lymph node status and invasion and metastasis [95]. 
Furthermore, Wisp1 has been shown to be involved in epithelial cell hyperplasia in 
breast cancer cell lines such as MCF-7, ZR-75, T47D and SKBR2 [58]. In lung 
cancer, Wisp1 expression was positively correlated to tumor histology, patient age 
and with lung cancer metastasis [96]. In esophageal cancer, Wisp1 positive cases 
were closely associated with tumor size and type, lymph node metastasis and poor 
prognosis [97]. In this line, we find Wisp1 up-regulation by immunohistochemistry in 
hepatocytes that show a pre-cancerogenous cell morphology. As HCC is a very 
heterogeneous disease [98], it is very unlikely that one individual marker can be 
correlated with all features  of HCC onset and progression. However, we could detect 
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the specific Wisp1 expression patterns in all HBV infected HCC patient samples. 
Presently, available markers for routine immunohistochemistry of HCC show different 
sensitivity towards the tumor stage and only very few of them are actually specific for 
HCC [99-102]. Together with AFP and GP-3 (member of the heparan sulfate 
proteoglycan family), Wisp1 might improve early detection of HCC in HBV patients. 
To test whether the up-regulation of Wisp1 in well differentiated HCC was of any 
functional significance we investigated different HCC cell lines since CCN protein 
functions have been shown to depend on the cell-type.  
 
 
HCC cell line proliferation or migration mediated by Wisp1 
 
Recent evidence indicates that Wisp1 can cause proliferation and migration of cancer 
cells and is involved in survival pathways [63, 103-105]. Importantly, Wisp1 is not 
limited to cancer cells since it has been found in different cell types including 
epithelial cells as well mesenchymal cells of different organs and tumors [51]. Thus, it 
remains unclear whether Wisp1 exerts its effects in the tumor cell itself or via the 
cellular microenvironment of the tumor.  
At the onset of our study, we were aware that hepatocellular carcinoma is highly 
heterogenous and ranges from well differentiated tumors to poorly differentiated 
neoplasms [9, 16]. Thus, we chose for in vitro studies two heterogenic HCC cell lines 
selected by the epithelial cadherin, E-Cadherin, which regulates cell-cell adhesions, 
mobility and proliferation of epithelial cells. The human hepatocellular carcinoma cell 
line FLC4 is well-differentiated, shows an epithelial phenotype and expresses E-
Cadherin (Fig.3-8). In contrast to the FLC4 cell line, the HCC cell line HLF is poorly 
differentiated, shows fibroblastoid phenotype and does not express E-Cadherin 
(Fig.3-5). We found that Wisp1 is expressed in both cell types (Fig.3-9). Expression 
of Wisp1 and its alternative splice variants were described in different HCC cell lines 
[60] and in vivo in HCC [61]. We also showed Wisp1 secretion from HCC cell lines in 
serum-free conditioned medium (Fig.3-9), suggesting Wisp1 as a serum marker for 
HCC and HCC specific serum markers are of great need [106, 107]. Recently, it was 
shown that Wisp1 overexpression resulted in morphological alterations of normal 
fibroblasts [57] and supports tumorigenesis [50, 57]. We further assumed a function 
of Wisp1 in HCC progression. Deregulation in cell proliferation and uncontrolled 
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growth have essential roles in carcinogenesis and are responsible for the cancer 
phenotype. The present study implies that Wisp1 exposure to the epithelial-cell type, 
either exogenous stimulation or overexpression, promotes DNA synthesis, while 
gene silencing of Wisp1 attenuates DNA synthesis in the FLC4 cell line (Fig.3-10 and 
Fig.3-12). In addition, we demonstrated that PCNA protein expression, accompanied 
by cyclinD1 and cyclinE1 RNA expression, is induced by Wisp1 in FLC4 cells 
whereas Wisp1 depletion is accompanied by reduced PCNA, cyclinA2 and cyclinD1 
levels. No effect was observed in response to Wisp1 stimulation in the fibroblastoid-
type HLF cell line. PCNA has been reported to be an indicator for cell proliferation; in 
HCC patients, high PCNA immunolabeling is associated with poor prognosis [108, 
109]. In vitro an increased amount of PCNA is expressed in the late G1 and S phases 
[110, 111]. An increase in cyclins, especially in cyclinD and cyclinE, are common in 
cancers, including HCC, as cyclins promote cell proliferation [112-114].  Especially 
the G1-phase cyclins (cyclinD1-3 and cyclinE) are discussed in this manner [115-
118], as they trigger the cells from the G1 to the S phase and this process 
determines the frequency of cell proliferation. In addition, the S-phase cyclinA [118] 
accompanies the cells through the S-phase [119, 120]. In the current study, we 
provide evidence that Wisp1 induced DNA synthesis in the epithelial-type HCC cell 
line is associated with promoting G1/S-phase and S-phase transition. Whereas 
Wisp1 is also described to be a negative regulator of proliferation, our data are in line 
with recent reports showing a proliferative effect of Wisp1 on epithelial cells [57, 58]. 
In this study, we provide further evidence that Wisp1 induced proliferation is cell type 
dependent. Since E-Cadherin is a marker of epithelial cell origin and an indicator of 
the epithelial phenotype,  it has a pivotal role in epithelial cell behavior during cancer 
progression and as it is down-regulated in numerous solid cancers, including 
hepatocellular carcinoma [121], we observed further the proliferative capacity of 
FLC4 E-Cadherin knockdown cells. We provide evidence that the proliferative 
capacity of E-Cadherin knockdown cells was not altered in comparison to control 
transfected cells, but Wisp1 induced proliferation in FLC4 cells was blocked after E-
Cadherin knockdown (Fig.3-14). However, E-Cadherin’s effect on proliferation is 
suggested to be complex and the decrease of proliferation in E-Cadherin transfected 
cancer cells has been described in numerous studies [122, 123], as well as increased 
cell proliferation [124, 125]. We suggest that the loss of E-Cadherin in FLC4 cells is 
associated with the loss of the epithelial cell phenotype, so that cells do not 
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proliferate after Wisp1 stimulation. Indeed the fibroblastoid phenotype HLF cells, 
which do not express E-Cadherin, do not proliferate after exposure to Wisp1 (Fig.3-
10). These findings can be attributed to cross-talk between E-Cadherin and integrins 
since recent investigations propose integrins as the main cell-surface receptors for 
CCN proteins [41, 77, 78]. There exists a large body of evidence that adhesion 
complexes of E-Cadherin and integrins effect carcinoma cell behavior [126] and 
especially hepatocellular carcinoma cells require integrins and cadherins for a a large 
number of cellular functions [127-129], thus the effects of Wisp1 in HCC are for 
certain complex. 
Furthermore, the loss of cell adhesions and, consequently, the invasion of 
surrounding tissue is although a major milestone during cancer development. CCN 
members are cell adhesive proteins to the ECM, they provide cell adhesion and 
motility. The fibroblastoid-type HLF cell line is described to strongly adhere, migrate 
and spread [66, 69]. In this work we were able to demonstrate that Wisp1 stimulation 
enhances both migration and adhesion in HLF cells (Fig.3-16) via downregulation of 
TIMP1. The balance between MMPs and their inhibitor TIMPs is associated with 
tumor cell mobility. According to our data, it has been reported that TIMP1 is an 
antimigrative factor [130-132] in liver diseases, but there is also evidence that TIMP1 
upregulation promotes cell migration [133]. Former studies show the effect of Wisp1 
on migration [47, 74] and recent evidence shows increased Wisp mediated migration 
via MMP2 expression in human chondrosarcoma cells through integrin receptors 
Fak, Mek, Erk, p65 and NF-κB signaling transduction [134]. Other studies also show 
that Wisp1 overexpression downregulates motility and invasion of lung cancer cells 
[47] or transfected Wisp1 K-1735 M-2 melanoma cells show decreased metastatic 
formation [49].  
Taken together, these data are in accordance with previous studies that show that 
the effects of CCN proteins on cell proliferation or migration are cell type dependent. 
For instance, in fibroblasts CCN1-3 induce DNA synthesis [78], although only CCN2 
(CTGF) is able to induce DNA synthesis in osteoblasts and chondrocytes [103, 104]. 
CCN3 mediates migration of Ewing’s sarcoma cells but blocks their proliferative 
capacity [135]. While CCN3 and CCN5 decrease vascular smooth muscle cell 
proliferation and migration, CCN1 and CCN2 act positively on the processes [105, 
136].  
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In the present study, we provide in vitro evidence that Wisp1 mediates proliferation of 
epithelial-type and migration of fibroblastoid-type cells. Whether these effects are in 
fact cell phenotype limited remains to be investigated deeper. Consistent with these 
in vitro data, revealed by immunohistochemical staining, we found a positive 
correlation between expression of E-Cadherin and Wisp1 (Fig.3-7). In early stage 
HCC, cancer cells are still in close connection due to strong cell-cell adhesions 
mediated by E-Cadherin. These cancer cells proliferate but do not leave their cell 
network. Due to EMT, these cancer cells lose E-Cadherin and their epithelial 
phenotype and at advanced stages of HCC start to migrate and to form metastasis.  
Furthermore, as it has been suggested that the functional properties of Wisp1 is 
dependent upon its ability to interact with a large number of partners involved in 
diverse signaling pathways, we further focussed our efforts on different HCC 
associated signaling targets. 
 
 
Wisp1 mediated signaling 
 
Detailed molecular pathways which play a pivotal role in the development of liver 
tumors are until now not fully identified [9, 137]. The mechanism through which 
Wisp1 mediates its diverse set of cellular and biological functions in isolated cell 
systems remains to be identified. However, current stories report a specific binding 
site for CCN proteins in integrin receptors [41, 45, 79, 138, 139]. In addition, 
activation of MAP kinases in general has been shown to be the main feature of 
several CCN family members, but their outcome varies, resulting in the same, 
different or even opposite effect on, for instance, proliferation, migration, adhesion or 
survival [54, 77, 140]. Thus, we focussed our work on oncogenic kinases which have 
been shown to be important mediators during HCC progression [116, 141, 142]. 
Rapid phosphorylation of focal adhesion kinases (Fak) and Src-kinases results in the 
activation of further downstream targets like P13/Akt or Ras/Raf/Erk, which are all 
important signal transduction pathways in hepatocellular carcinoma [44, 46, 143, 
144]. Clinical studies showed the critical involvement of Akt phosphorylation in the 
aggressiveness of HCC [145] and activation of Erk has been described to be 
adhesion-dependent [146, 147]. In this study, we demonstrate that Wisp1 treatment 
causes activation of Fak, Src, Akt and Erk1/2 via phosphorylation, whereas no 
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activation of p38 or c-Jnk was observed (Fig.3-15). Activation of these signaling 
targets was comparable in epithelial- and fibroblastoid-type HCC cell lines. Moreover, 
silencing of endogenous Wisp1 expression leads not only to alterations in 
phosphoprotein but also in unphosporylated protein level in the epithelial-type HCC 
cell line FLC4 (Fig.3-15). These findings are supported by other studies which show 
the involvement of the Fak signaling pathway in response to Wisp1 in 
chondrosarcoma cells [134] or  which demonstrate Akt activation in response to 
Wisp1 [54, 74], whereas Wisp1 induced cell motility of the HuCCT1 
cholangiocarcinoma cell line and was shown to be mediated through activation of p-
p38 [62].Thus, our findings demonstrate first, Wisp1 mediated signaling in HCC cell 
lines and second, signaling is cell type independent but results in cell type dependent 
effects. Previous studies show that Wisp1 attenuated p53 mediates apoptosis 
through activation of Akt [54] and induces expression of BCL-2 and BCL-XL [73]. 
Since activation of Akt pushes for cells survival and blocks apoptosis by involvement 
of BCL-XL and activation of the intrinsic caspase mechanism [148, 149], we found 
consequently that Wisp1 FLC4 knockdown cells show a decrease of anti-apoptotic 
BCL-XL protein level, an increase in Caspase 3 activity, and increase in Akt level and 
go into apoptosis and not into proliferation in culture (Fig.3-10 and Fig.3-17). The 
impact of CCN proteins on apoptosis has mainly been shown for CCN1-3 which 
activate tumor necrosis factor (TNF) to induce apoptosis [150]. In contrast, Wisp1 
inhibits TNF-induced cell death in cardiomyocytes [151]. This study shows that Wisp1 
mediated mechanisms of inflammation in HCC cell lines is associated with regulation 
of apoptotic pathways. As apoptosis is inhibited in cancer cells and this inhibition 
contributes to cancer progression, many anticancer reagents activate apoptosis of 
cancer cells [152, 153]. As we have shown that Wisp1 depletion in cancer cells 
increases apoptosis, it is tempting to conclude that and increase in the level of Wisp1 
is a pro-apoptotic protein would be suitable for cancer treatment. 
 
In conclusion, we provide evidence that Wisp1 might serve as a marker for the early 
detection of HCC since we found its expression is associated with well differentiated 
HCC and its expression and secretion in phenotype differing HCC derived cell lines. 
Our studies show in addition that Wisp1 mediated signaling in HCC cell lines is cell 
type independent and leads to a cell type dependent response (Fig.4-1). 
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Fig.4-1. Scheme of the main findings of this study. A. In vivo and B. In vitro.
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5 Summary 
Worldwide, primary hepatocellular carcinoma is the fifth most commonly diagnosed 
solid cancer and the third most common cause of cancer related death. Because of 
its constantly increasing incidence in developed countries and its poor prognosis, 
HCC represents a major health problem. Diagnostic markers for early-stage HCC are 
of great need but still lacking due to the high complexity and heterogeneity of HCC. 
The purpose of this study was to examine Wisp1 expression in different liver tumor 
stages and its functional role in epithelial- and fibroblastoid-type HCC cell lines. By 
immunohistochemical staining of HCC patient samples, we demonstrated that Wisp1 
expression is enhanced in well- and moderately differentiated  HCC and is 
associated with inflammation and steatosis, but is absent in poorly differentiated 
HCC. Furthermore, we found that Wisp1 is expressed and secreted in HCC cell lines 
(FLC4, HLF). Treatment of the epithelial-type HCC cell lines with human recombinant 
Wisp1 led to an increase in proliferation, while fibroblastoid-type HCC cell lines 
showed an increase in migration. Interestingly, both types of cell lines displayed the 
activation of the same phosphokinases upon Wisp1 stimulation. Knockdown of Wisp1 
with shRNA in the epithelial-type HCC cell line consequently decreased proliferation 
and, more importantly, led to apoptosis. 
Our study thus identified Wisp1 as a novel immunohistochemical marker for the 
detection of well differentiated, early-stage HCC as well as a regulator of proliferation 
in the epithelial-type HCC cell line and a regulator of migration in the fibroblastoid-
type HCC cell lines via activation of distinct HCC related phosphokinases. These 
results pose Wisp1 as a possible diagnostic marker for HCC for which currently only 
poor therapies are available. 
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8 Appendix 
8.1 Abbreviations 
AFP  α–fetoprotein 
BrdU  5-bromo-2’-deoxy-uridine 
Bromo- 
phenol  
Blue  3',3",5',5"-tetrabromo-
ophenolsulfonphthalein 
BSA   bovine serum albumin 
CCN  Cystein61/CTGF/Nov 
cDNA  copy deoxyribonucleic 
acid 
CHAPS 3-[(3-Cholamidopropyl) 
dimethylammonio]- 
1-propanesulfonate 
CTGF  connective tissue growth 
factor 
d   days 
DAB   3,3´-diaminobenzidine- 
tetrahydrochloride 
dH2O  distilled water 
ddH2O  double distilled water 
DEPC  Diethylpyrocarbonate 
DMEM  Dulbecco’s modified 
Eagle’s medium 
DMSO  dimethyl sulfoxide 
DNA   deoxyribonucleic acid 
dNTP   deoxynucleotide 
triphosphate 
DOC  Deoxycholic acid 
Na-salt 
DTT   1,4-Dithiothreitol 
E.coli  Escherichia coli 
EtBr  Ethithium bromide 
EtOH   ethanol 
ECL   enhanced 
chemiluminescent 
EDTA   ethylenediamine-
tetraacetic acid 
tetrasodium salt 
EMT epithelial-mesenchymal 
 transition 
f   forward primer 
FCS  fetal calf serum 
Fig.   figure 
FS  forward scatter 
 
 
 
 
 
 
 
g   grams  
GFP green fluorescent 
 protein 
GSK-3β glycogen synthase kinase 
beta 
kDa   kilo Dalton 
h  hour 
HBV  hepatitis B virus 
HCV  hepatitis C virus 
HCC  hepatocellular carcinoma 
HC  hepatocytes 
HSPG  heparan sulfate 
proteoglycan 
L-Glu  L-glutamine 
LSM  laser-scanning confocal 
microscopy 
NOV  nephroblastoma 
overexpressed 
NAFLD non-alcoholic fatty liver 
 disease 
M   moles per liter 
MAPK  mitogen-activated protein 
kinase 
mM   millimoles per liter 
µM   micromoles per liter 
mol  mole 
MOPS  3-(N-morpholino)- 
propanesulfonic acid 
MW   molecular weight 
mol   mole 
NaOH  sodium hydroxide 
NaOAc Sodium acetate 
PBS   phosphate buffered saline 
PCNA  proliferating cell nuclear 
antigen 
PCR   Polymerase chain 
reaction 
PFA Paraformaldehyde 
POD peroxidase 
P/S   Penicillin-streptomycin 
r   reverse primer 
RNA  ribonucleic acid 
RT  room temperature 
SDS   sodium dodecyl sulfate 
sec  seconds 
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shco  short hairpin control 
SS  side scatter 
shRNA  short hairpinRNA 
Tab.  table 
TBE   Tris-borate-EDTA buffer 
TBS   Tris-buffered saline 
TBST   Tris-Tween-buffered  
TE   Tris-EDTA buffer 
TEMED  N,N,N',N'-Tetramethyl-
ethylenediamine 
TGF-β transforming growth 
factor beta 
TMB tetramethyl-benzidine 
Tris Tris(hydroxymethyl)- 
 aminomethane 
U  units 
VEGF vascular endothelial 
growth factor 
Wisp1  Wnt-inducible signaling 
protein 1
Appendix 
 
96 
 
8.2 Primers 
 
Tab. 8-1 Table of primer sequences. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gene sequence primer 
beta-actin 
 
cyclin A2 
 
cyclin B2 
 
cyclin D1 
 
cyclin E1 
 
Timp1 
 
Timp1 
 
Wisp1 
5’-cacccacactgtgcccatc-3’ 
5’-ctcctgcttgctgatccac-3’ 
5’-gcaccccttaaggatcttcc-3’ 
5’-cctctcagcactgacatgga-3’ 
5’-gtatctcaggcagctggagg-3’ 
5’-gaagccaagagcagagcagt-3’ 
5’-catgaactacctggaccgct-3’ 
5’-tcactctggagaggaagcgt-3’ 
5’-ggtatacttgctgcttcggc-3’ 
5’-tctttggtggagaaggatgg-3’ 
5’-cctgtgtcccaccccaccca-3’ 
5’-caggcaggcaaggtgacggg-3’ 
5’-ggcagtgtgtggggtctcgc-3’ 
5’-cggtgccaaggcagggactg-3’ 
5’-atgaggtggctcctgcct -3’ 
5’-caaaggctctggtgtccaa -3’ 
beta-actin _f 
beta-actin _r 
cyclin A2 _f 
cyclin A2 _r 
cyclin B2 _f 
cyclin B2 _r 
cyclin D1 _ f 
cyclin D1 _r 
cyclin E1 _f 
cyclin E1 _r 
Timp1_f 
Timp1_r 
Timp2_f 
Timp2_r 
Wisp1 _f 
Wisp1 _r 
Appendix 
 
97 
 
8.3 Antibodies 
8.3.1  Primary antibodies 
 
Tab. 8-2 Table of primary antibodies. 
 
 
 
 
 
antibody origin application (dilution) source 
Akt 
 
BCL-XL 
 
E-Cadherin 
 
 
 
 
 
Erk1/2 
 
Fak 
 
GAPDH 
 
Wisp1 
 
 
 
pAkt 
 
PCNA 
 
pErk1/2 
 
pFAk397 
 
pSrc 
 
Src 
 
Tubulin 
 
polyclonal rabbit 
 
polyclonal rabbit 
 
polyclonal mouse 
 
 
 
 
 
polyclonal mouse 
 
polyclonal rabbit 
 
polyclonal rabbit 
 
polyclonal rabbit 
 
 
 
polyclonal mouse 
 
polyclonal mouse 
 
polyclonal rabbit 
 
polyclonal rabbit 
 
polyclonal rabbit 
 
polyclonal rabbit 
 
polyclonal rabbit 
Western blot 
(1:1,000) 
Western blot 
(1:1,000) 
Western blot 
(1:1,000) 
Immunohistochemistry 
(1:200) 
Immunofluorescence 
(1:100) 
Western blot 
(1:1,000) 
Immunofluorescence 
(1:100) 
Western blot 
(1:1,000) 
Western blot 
(1:1,000) 
Immunohistochemistry 
(1:200) 
Western blot 
(1:1,000) 
Western blot 
(1:1,000) 
Western blot 
(1:1,000) 
Western blot 
(1:1,000) 
Western blot 
(1:1,000) 
Western blot 
(1:1,000) 
Western blot 
(1:1,000) 
Cell Signaling (9272) 
 
Cell Signaling (2764) 
 
BD Bioscience 
(610181) 
 
 
 
 
Santa Cruz (sc-135900) 
 
Santa Cruz (sc-557) 
 
Santa Cruz (sc-25778) 
 
Abcam (ab10737) 
 
 
 
Cell Signaling (4051S) 
 
Santa Cruz (sc-25280) 
 
Santa Cruz (sc-7383) 
 
Santa Cruz  
(sc-11765-R) 
Cell Signaling (2113-S) 
 
Cell Signaling (2109) 
 
Abcam (ab4074-100) 
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8.3.2  Secondary antibodies 
 
Tab. 8-3 Table of secondary antibodies. 
 
 
antibody origin application (dilution) source 
anti-rabbit-HRP 
 
anti-mouse-HRP 
 
anti-rabbit- 
immunoglobulins/HRP 
 
Alexa®488 
anti-rabbit 
 
Alexa®488 
anti-mouse 
 
goat 
 
goat 
 
swine 
 
 
goat 
 
 
goat 
 
 
Western blot 
(1:5,000) 
Western blot 
(1:1,000) 
Immunohistochemistry 
(1:200) 
 
Immunofluorescence 
(1:300) 
 
Immunofluorescence 
(1:300) 
 
Santa Cruz (sc-2301) 
 
Santa Cruz (sc-2005) 
 
Dako (2016-02) 
 
 
Invitrogen (A11029) 
 
 
Invitrogen (A11008) 
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